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ABSTRACT 
Buprenorphine and fentanyl are opioids, which have been clinically used for 
decades. Buprenorphine is traditionally prescribed for maintenance therapy in opioid 
dependent patients and to a lesser extent in the treatment of acute pain. Fentanyl is 
the most widely used perioperative opioid. In recent years new dosage forms have 
been introduced for both of these drugs. The use of buprenorphine in the treatment 
of chronic pain has increased with the introduction of sublingual and transdermal 
formulations. Good results have been obtained with the administration of sublingual 
fentanyl in the treatment of cancer breakthrough pain.  
Some interaction studies have been made using high-dose buprenorphine and 
antiretrovirals, but there are few studies evaluating the drug-drug interactions 
between low-dose buprenorphine and known CYP3A4 inhibitors and inducers. In 
this thesis three studies were conducted to study the interactions between 
buprenorphine, using three different administration routes, and two CYP3A4 
inhibitors, voriconazole and posaconazole and the CYP3A4 inducer, rifampicin.   
Voriconazole increased significantly the plasma concentration of sublingually 
and orally administered buprenorphine. Posaconazole also increased the plasma 
concentration of sublingually administered buprenorphine but the effect was not as 
evident as that encountered with voriconazole. Rifampicin decreased the plasma 
concentrations of sublingually administered buprenorphine, but it had no effect after 
the opioid’s intravenous administration.  
The aim of the fourth study was to evaluate the efficacy and safety of a 
sublingually administered fentanyl tablet in patients having colonoscopy. Patients 
often experience colonoscopy painful and unpleasant. Intravenous sedation increases 
the costs of colonoscopy significantly because patients need monitoring during 
sedation and recovery. The use of the sublingual administration route could offer a 
cost-effective alternative to intravenous sedation. 
This study showed that 100 micrograms of sublingual fentanyl was ineffective 
for the treatment of pain during colonoscopy. Nonetheless, it was observed that very 
few procedures had to be interrupted and the pain that patients experienced was 
mostly moderate. This raises the question of whether we should treat patients for 
anxiety and distress instead of pain.  
KEYWORDS: buprenorphine, voriconazole, posaconazole, rifampicin, 
pharmacokinetics, drug-drug interaction, pain, colonoscopy, sublingual fentanyl, 
analgesia, endoscopy 
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TIIVISTELMÄ 
Buprenorfiini ja fentanyyli ovat opioideja, jotka ovat olleet kliinisessä käytössä 
vuosikymmeniä. Buprenorfiinia käytetään yleisimmin opioidiriippuvaisten 
potilaiden vieroitus- ja korvaushoidossa ja jonkin verran akuutin kivun hoidossa. 
Fentanyyli on eniten käytetty perioperatiivinen opioidi. Molemmista lääkkeistä on 
viime vuosina tullut markkinoille uusia annostelumuotoja. Buprenorfiinin käyttö 
kroonisen kivun hoidossa on lisääntynyt sublinguaalisen ja transdermaalisen 
annostelumahdollisuuden myötä. Sublinguaalisen fentanyylin käytöstä on saatu 
hyviä tuloksia syövän läpilyöntikivun hoidossa.  
Kirjallisuus ei juurikaan tunne buprenorfiinin interaktioita muiden kuin HI-
virusinfektioon käytettävien lääkkeiden kanssa ja näissä tutkimuksissa on ollut 
käytössä buprenorfiinin korkeampi korvaushoitoannos. Tämän tutkimuksen 
kolmessa työssä tutkittiin eri annostelureittejä annetun buprenorfiinin farmako-
kineettisiä ja farmakodynaamisia yhteisvaikutuksia CYP3A4-entsyymin toimintaa 
estävien vorikonatsolin ja posakonatsolin kanssa sekä CYP3A4-entsyymin toimintaa 
kiihdyttävän rifampisiinin kanssa.   
Vorikonatsoli lisäsi merkittävästi sublinguaalisesti ja oraalisesti annostellun 
buprenorfiinin pitoisuuksia plasmassa. Myös posakonatsoli lisäsi sublinguaalisesti 
annostellun buprenorfiinin pitoisuutta plasmassa, mutta vaikutus oli huomattavasti 
pienempi kuin vorikonatsolilla. Rifampisiini pienensi sublinguaalisesti annostellun 
buprenorfiinin pitoisuutta veressä, mutta sillä ei ollut vaikutusta suonensisäisesti 
annostellun buprenorfiinin pitoisuuksiin.  
Neljännessä työssä arvioitiin kielen alle annostellun fentanyylin tehoa ja 
turvallisuutta paksusuolen tähystyksen esilääkkeenä. Paksusuolen tähystys koetaan 
hyvin kivuliaana ja epämiellyttävänä tutkimuksena. Suonensisäinen sedaatio ja 
kivunlievitys kuitenkin nostavat merkittävästi toimenpiteen kustannuksia ja lisäävät 
siihen kuluvaa aikaa, koska potilaat tarvitsevat suoniyhteyden ja heitä täytyy seurata 
sedaation aikana ja sen jälkeen. 
Tämä tutkimus osoitti, että kielen alle annostellulla fentanyylillä annoksella 100 
µg ei pystytä lievittämään potilaiden kokemaa kipua paksusuolen tähystyksen 
aikana. Tutkimus osoitti myös sen, että kipu on harvoin tutkimuksen rajoittava tekijä 
ja herätti ajatuksia siitä, tulisiko pyrkiä hoitamaan potilaiden kokemaa ahdistusta ja 
epämukavuuden tunnetta kivun sijaan. 
AVAINSANAT: Buprenorfiini, vorikonatsoli, posakonatsoli, rifampisiini, 
farmakokinetiikka, lääkeinteraktio, kipu, kolonoskopia, sublinguaalinen fentanyyli, 
tähystystoimenpide   
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1 Introduction 
The number of clinically used medicines and their formulations increase year by 
year. Although buprenorphine and fentanyl are traditional opioids their clinical 
applications have become more diverse in recent years because of the development 
of new dosage forms. The use of buprenorphine has increased in the treatment of 
chronic pain when sublingual and transdermal administration have become 
available. Sublingually administered fentanyl has been found to be effective and safe 
in the treatment of cancer breakthrough pain.  
It is very common that several drugs are used concomitantly and the risk of drug-
drug interactions (DDIs) has increased (Åstrand et al. 2007). Most DDIs are harmful, 
but some of them lead to serious adverse effects (Bucşa et al. 2013). The chemical 
properties of drugs and many patient-related factors, such as the patient’s age, 
gender, weight and concomitant diseases, affect the pharmacokinetics of the drug. 
One of the most common causes for harmful DDIs is inhibition of cytochrome P-
450 (CYP) mediated metabolism of the drug (Pelkonen et al. 2008). Recent studies 
have also shown that other systems, such as membrane transporters and UDP- 
transferases (UGTs) can have their role in drug metabolism and interactions  (Chang, 
Moody, and McCance-Katz 2006; Hassan et al. 2009). 
Buprenorphine is a semisynthetic partial µ-opioid receptor agonist. It is widely 
used in the treatment of opioid withdrawal symptoms and in the maintenance therapy 
of opioid-dependent patients. In much lower doses, it is prescribed as an analgesic 
agent and in recent years transdermal formulations have increased its use in the 
treatment of moderate chronic pain (Fredheim et al. 2010; Zin, Chen, and Knaggs 
2014). Some interaction studies have been conducted using high-dose buprenorphine 
and antiretrovirals (McCance-Katz et al. 2007; 2006), but the interactions of low-
dose buprenorphine are largely unknown. 
The bioavailability of oral buprenorphine is very low due to first-pass 
metabolism. Sublingual buprenorphine has higher bioavailability, although data 
from different studies are very variable (Bullingham et al. 1982; Kuhlman et al. 
1996; Mendelson et al. 1997). The principal metabolic pathway, N-dealkylation of 
buprenorphine is catalysed mainly by cytochrome P450 (CYP) 3A4 (Cone et al. 
1984). Some transporters such as P-glycoprotein and UGTs can play a role in the 
Mari Fihlman 
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pharmacokinetics of buprenorphine and its metabolites (Chang, Moody, and 
McCance-Katz 2006; Alhaddad et al. 2012; Brown et al. 2012). Since strong opioids 
like buprenorphine can exert serious adverse effects such as respiratory depression, 
it is important to study these potentially hazardous DDIs with drugs which are known 
to inhibit or induce CYP-mediated metabolism. 
The development of medicine and technology has enabled more and more 
diseases to be diagnosed at an early stage. Most of the diagnostic imaging and 
procedures can be performed without anaesthesia, but nowadays patients are more 
aware of the possibility of receiving pain relief or sedation. Implementation of 
sedation demands that these patients are monitored during and after the procedure 
and obviously this increases costs and time spent handling one patient. 
Colonoscopy is an invasive procedure that can cause pain and discomfort to the 
patient. Most patients value analgesia during colonoscopy (Subramanian, 
Liangpunsakul, and Rex 2005) but instead sedatives are still commonly used to 
decrease anxiety and to treat pain during colonoscopy (Porostocky et al. 2011; 
Froehlich et al. 2006). Fentanyl is a rather short-acting opioid and a transmucosal 
sublingual delivery form has been developed to improve the management of 
breakthrough pain in cancer patients. Analgesia by administering a transmucosal 
tablet during colonoscopy is a novel approach and low doses of intravenous fentanyl 
seem to be effective in achieving a satisfactory level of comfort during colonoscopy 
(Lazaraki et al. 2007). A single dose of sublingual fentanyl does not require follow-
up after the procedure, and thus it was hypothesized that sublingual fentanyl could 
be a non-invasive and cost-effective way to provide adequate analgesia and increase 
patient satisfaction during colonoscopy. 
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2 Review of the Literature 
2.1 Opioids studied 
2.1.1 Buprenorphine 
Buprenorphine was approved for clinical use in the United Kingdom in 1978 as an 
injectable formulation for the  treatment  of  moderate  to  severe  pain and a 
sublingual  tablet form was launched in 1981 (Cowan 2007).  Buprenorphine has 
been used to treat heroin addiction since 1996 when it was first introduced in 
France for this purpose. Buprenorphine, a derivative of oripavine has unusual 
receptor-binding properties. Buprenorphine is a partial µ-opioid receptor agonist 
which antagonizes the ĸ-opioid receptor and acts as an agonist at the δ-opioid 
receptor and the opioid receptor-like receptor (Dum and Herz 1981; Leander 
1987). The analgesic efficacy of buprenorphine is 20-40 times higher than 
morphine and it produces long-lasting subjective and physiological effects 
(Mattick et al. 2003). The possibility to administer the drug once a day or even less 
frequently is a great benefit when treating chronic pain or opioid dependency. 
Buprenorphine is considered safe in clinical use because of its ceiling effect. The 
ceiling effect is evident i.e. increasing the drug dose no longer exerts any effect on 
an important dependent variable, in this case depression of respiration.  It is well 
known that the most common severe adverse effect of opioids is respiratory 
depression (Helpern and Rho 1967) and it is recognized that both sublingual and 
intravenous administration routes of buprenorphine even at high doses have good 
safety margin for respiratory depression because of the ceiling effect (Umbricht et 
al. 2004; Walsh et al. 1994). It has been shown that after the administration of 16 
mg sublingual buprenorphine respiration was maximally suppressed and higher 
doses of buprenorphine did not cause more intense respiratory depression (Walsh 
et al. 1994). There are some studies suggesting that this ceiling phenomenon might 
be due to pharmacokinetic factors (Harris et al. 2004) whereas others have found 
indications that the ceiling effect is most likely caused by pharmacodynamic 
adaptation, at least up to the dose of 12 mg (Huestis et al. 2013).  
Mari Fihlman 
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2.1.2 Pharmacokinetics of buprenorphine 
Buprenorphine undergoes extensive metabolism; in particular, considerable first 
pass metabolism. Buprenorphine has a very low oral bioavailability (around 10-
16%). Sublingual bioavailability is higher (30-55%) but different studies report very 
variable data (Bullingham et al. 1982; Kuhlman et al. 1996; Mendelson et al. 1997; 
Nath et al. 1999). Absorption to systemic circulation is slow and the mean time to 
reach the maximum concentration after sublingual administration has been claimed 
to lie in a range of 40 – 210 minutes (Kuhlman et al. 1996; Nath et al. 1999; 
Bullingham et al. 1981).  
Buprenorphine has a large volume of distribution, which is estimated to be 188-
335L following intravenous administration (Kuhlman et al. 1996; Bullingham et al. 
1980). Buprenorphine is highly lipophilic and it is extensively bound to plasma 
proteins (96%) (Elkader and Sproule 2005).  
The main metabolic pathway (65%) of buprenorphine is N-dealkylation to an 
active metabolite norbuprenorphine. This pathway is catalysed mainly by 
cytochrome P450 (CYP) 3A4, but also by CYP3A5 and CYP2C8 (Iribarne et al. 
1997; Moody et al. 2002; Picard et al. 2005; Chang, Moody, and McCance-Katz 
2006). Buprenorphine and norbuprenorphine are further conjugated to 
buprenorphine-3-glucuronide (B3G) and norbuprenorphine-3-glucuronide (N3G) by 
UGTs (Chang, Moody, and McCance-Katz 2006). These metabolites have receptor 
binding properties and pharmacological activity according to animal studies (Brown 
et al. 2011). Other oxidized and hydroxylated metabolites are formed by other 
metabolic pathways (Chang, Moody, and McCance-Katz 2006; Picard et al. 2005). 
(Fig. 1.) The elimination half-life of buprenorphine is long and there is considerable 
variation in values obtained. Sublingual buprenorphine is reported to have a mean 
elimination half-life from plasma of 37 hours (Elkader and Sproule 2005). 
Buprenorphine is mainly excreted as metabolites in bile (80-90%) and urine (10-
30%) (Brewster, Humphrey, and McLeavy 1981; Cone et al. 1984). The majority of 
the metabolites are excreted into the biliary system and they can be subject to 
enterohepatic circulation (Brewster, Humphrey, and McLeavy 1981).  Subsequent 
studies have also shown, that many opioids are substrates of transporter proteins, 
such as P-glycoprotein, which can affect their metabolism (Dagenais, Graff, and 
Pollack 2004; Kharasch et al. 2003; Drewe et al. 2000). 
The main metabolite of N-dealkylation, norbuprenorphine is found in high 
concentrations in urine and urine toxicology tests are frequently used for patients in 
buprenorphine maintenance therapy for the determination of the adherence to 
treatment. If buprenorphine is administered by a route that bypasses first-pass 
metabolism totally (eg. intravenously or subcutaneously), the formation of 
norbuprenorphine is significantly lower (Kuhlman et al. 1996). 
Review of the Literature 
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Figure 1.  Metabolism of buprenorphine. Modified from Vicencio-Rosas et al. 2018.  
2.1.3 Clinical use 
Treatment of opioid dependence 
Buprenorphine was approved for the treatment of opioid addiction in the United 
States in October 2002. It had been already used for this purpose in France since 
1996. Buprenorphine has many features that make it an excellent drug for the 
treatment of opioid dependence. It does not induce significant physical dependence 
and there is a small possibility of lethal overdose without concomitant use of other 
drugs or alcohol (Mello and Mendelson 1985). Sublingual buprenorphine has a long 
elimination half-life and dosing once a day or even less frequently is possible. 
Buprenorphine is a rather safe drug and it has a lower risk of causing respiratory 
depression than full opioid agonists (Umbricht et al. 2004). Many opioid dependent 
patients fail in their attempt to stop opioid use. It has been shown that long term 
maintenance therapy with buprenorphine is feasible and effective in many respects 
(Gossop et al. 1989; Fudala et al. 2003). In a recent analysis conducted in France, 
patients who discontinued prescribed buprenorphine treatment were 29 times more 
likely to die compared to patients who stayed in the buprenorphine treatment 
programme (Dupouy et al. 2017). 
The most common sublingual doses used in maintenance therapy are 8-16 mg. 
Studies have shown that moderate-to-high doses have significantly higher efficacy 
Mari Fihlman 
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than lower doses (1-3 mg) (Ling et al. 1998; Ahmadi 2003). Sublingual 
buprenorphine has been even administered successfully three times a week in 
maintenance therapy (Schottenfeld et al. 2000; Pérez De Los Cobos et al. 2000). 
Sublingual form of buprenorphine where naloxone is combined with 
buprenorphine (Suboxone®) to reduce the intravenous misuse of buprenorphine, is 
commonly used in maintenance therapy.  Naloxone has poor bioavailability when 
administered sublingually, but if buprenorphine-naloxone is taken inappropriately 
e.g. by parenteral routes, the presence of naloxone in the bloodstream will induce 
withdrawal symptoms (Chiang and Hawks 2003; Weinhold et al. 1992).  
The most novel approach in the treatment of opioid dependence are the long-
acting formulas approved recently. The subdermal buprenorphine implant was 
approved in the USA in May 2016 and in European Union in June 2019. It is 
designed to provide a constant low-level dose of buprenorphine for six months for 
patients in maintenance therapy (Smith et al. 2017). The product consists of 4 thin 
rods each containing 80 mg (total 320 mg) of buprenorphine. With this new product 
a steady-state concentration slightly less than that produced by 8 mg daily sublingual 
buprenorphine can be achieved. This is recommended for patients who are already 
stable with 8 mg or less daily sublingual buprenorphine (Ling et al., 2010). Another 
recently approved long-lasting formula is a monthly subcutaneous injection depot 
which was approved in the USA in late 2017. It is available in two doses: 100 mg 
and 300 mg. The recommended dosing regimen is two 300 mg monthly doses 
followed by 100 mg doses thereafter (Coe, Lofwall, and Walsh 2019). This injectable 
product produces much higher plasma concentrations of buprenorphine and 
therefore it is recommended for patients who already have higher daily 
buprenorphine doses and greater physical dependency. Another subcutaneous 
buprenorphine formula is approved in the European Union and is already in clinical 
use in Finland. Available dosage range of this buprenorphine formula is from 8 mg 
to 128 mg and it is administered first weekly and after achieving the steady state the 
administration can be implemented monthly.  
These new products could alleviate many patient concerns such as having their 
prescription stolen, needing to safely store their medicine away from children and 
travelling while carrying controlled, and in some countries, illegal, substances.  
Acute pain 
Buprenorphine has been thought to be a safe drug because of its ceiling effect on 
respiratory depression. Only in recent years have we learned that there is no ceiling 
effect for the analgesic effect of buprenorphine (Dahan et al. 2006). For this reason 
buprenorphine is considered to be very useful in the management of acute pain and 
in fact, it has been shown that there is no difference in the analgesia provided by 
Review of the Literature 
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either buprenorphine or morphine (White et al. 2018). The duration of one dose is 6-
8 hours and adverse effects are less common than with morphine (Walsh et al. 1994). 
Buprenorphine is used for the treatment of acute pain intravenously at a dose of 
0.3 mg and sublingually at a dose of 0.2-0.4 mg. Buprenorphine is a very potent 
analgesic, with an intravenous dose of 0.3 mg being equivalent to 10 mg of morphine 
in patients who are not dependent on opioids. It has been demonstrated that 
buprenorphine is effective in the treatment of acute pain even when administered via 
intrathecal (Celleno and Capogna 1989), epidural (Inagaki, Mashimo, and Yoshiya 
1996), subcutaneous  or intra-articular (Varrassi et al. 1999) route or when combined 
with regional anaesthesia (Candido et al. 2002). 
Chronic pain 
The use of strong opioids has increased in the treatment on non-malignant moderate 
to severe pain (Breivik et al. 2006). New dosage formulations of buprenorphine have 
increased the interest to use buprenorphine in the treatment of chronic pain.  
Sublingual buprenorphine has been found to be effective in the treatment of 
chronic pain (Cote and Montgomery 2014). Due to its unique pharmacological 
profile, buprenorphine has an increased efficacy in treating neuropathic pain 
(Pergolizzi et al. 2008; Davis 2012). It is safe to use because of the ceiling effect for 
respiratory depression when used without other central nervous system depressants 
(Johnson, Fudala, and Payne 2005; Pergolizzi et al. 2008). The adverse effects in 
sublingual buprenorphine therapy have been found to be similar to standard opioid 
therapy (Cote and Montgomery 2014). 
Transdermal drug delivery systems, so called opioid patches offer an ideal route 
of administration to achieve minimal variation in opioid plasma levels. When the 
drug is administered transdermally, the duration of the analgesic effect is longer and 
there are fewer adverse effects.  Buprenorphine is an ideal drug for transdermal 
delivery because of its good lipophilicity (Sittl, Griessinger, and Likar 2003; 
Johnson, Fudala, and Payne 2005). 
In Finland, transdermal buprenorphine is available with several different patch 
strengths ranging from 5 µg/hour to 40 µg/hour. Transdermal buprenorphine patches 
have been found to be effective and well-tolerated in the treatment of malignant and 
non-malignant chronic pain (Sittl, Griessinger, and Likar 2003; Griessinger, Sittl, 
and Likar 2005). Transdermal buprenorphine has also been found to be safe in 
patients who have renal insufficiency (Hand et al. 1990) as well as in elderly patients 
(Likar et al. 2008). 
Buccal buprenorphine was approved for clinical use in the USA in 2015. It was 
developed for the treatment of chronic pain and is approved for the treatment of pain 
severe enough to require long term opioid therapy where alternative treatment 
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opioids are inadequate. It is made from a  flexible, water-soluble polymeric film, 
which ensures rapid absorption and provides a possibility to titrate doses in a  flexible 
manner (Aiyer et al. 2018). This formulation has been found to be promising in the 
treatment of chronic back pain (Rauck et al. 2016). 
Other indications 
Buprenorphine is currently investigated for the treatment of depression (Karp et al. 
2014) due to its ability to bind also to kappa opioid receptors. There is some evidence 
that kappa receptors are involved in the stress system and in the pathophysiology of 
depression (Crowley and Kash 2015). Low dose buprenorphine has been found to be 
effective and well-tolerated in reducing depressive symptoms even in patients with 
treatment-resistant depression (Karp et al. 2014; Ehrich et al. 2015; Serafini et al. 
2018). Furthermore, there are indications that buprenorphine could significantly 
reduce suicidal ideation (Striebel and Kalapatapu 2014; Ahmadi, Sarani, and 
Jahromi 2020). 
2.1.4 Sublingual fentanyl as an analgesic agent 
Fentanyl has a long history as the most common intraoperative opioid. Fentanyl has 
a significant role in the treatment of acute and chronic pain and it can be administered 
intravenously, transdermally and transmucosally (Stanley 2014). The primary sites 
of therapeutic action of fentanyl are the µ-opioid receptors in the central and 
peripheral nervous system (Darwish et al. 2007). Fentanyl is a very potent analgesic 
agent and it is flexible to use because there are various formulations available. A 
broad range of drug-drug interactions influence significantly its serum 
concentrations. Fentanyl is highly lipophilic allowing it to diffuse easily across 
biological membranes (Stanley 2005).  
Sublingual fentanyl oral dosage forms are approved for the treatment of 
breakthrough pain in cancer patients already receiving other forms of opioid therapy 
(Portenoy et al. 2006; Weinstein, Messina, and Xie 2009). It has been administered 
also to patients with severe non-malignant chronic pain  and it has been found to be 
effective, safe and well-tolerated (Portenoy et al. 2007; Simpson et al. 2007). The 
use of sublingual fentanyl has been shown to improve the quality of life in patients 
suffering from breakthrough pain (Guitart et al. 2015; Cánovas-Martínez et al. 2015). 
It has been proven to be safe also in elderly patients (Guitart et al. 2019).  
Sublingual administration of fentanyl is beneficial due to the rapid onset of 
action and the avoidance of extensive and variable CYP3A4 mediated metabolism 
in gut and liver (Zhang et al. 1997). Bioequivalence of buccally and sublingually 
administered fentanyl was studied in healthy subjects by using a single fentanyl dose 
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of 400 µg. The systemic exposure following buccal and sublingual administration 
was found to have similar effects (Darwish et al. 2008). The drug was also well 
tolerated and patients experienced no severe adverse effects. The most common 
adverse effects after administration of sublingual fentanyl include nausea, vomiting, 
somnolence and constipation, which are commonly observed with opioid analgesics 
(Guitart et al. 2013).   
The bioavailability of buccal fentanyl is approximately 65 % (Darwish et al. 
2007). After absorption, fentanyl is known to exhibit a quick onset and a short 
duration of drug effect. It has been shown that after sublingual administration of 
fentanyl, the first detectable concentrations in plasma are observed in 8-10 minutes 
and the maximum concentration is reached in 40-50 minutes (Lennernäs et al. 2005). 
Patients receiving sublingual fentanyl for breakthrough cancer pain have reported 
the first effect of the drug within 5 minutes of administration and a maximum effect 
within 30 minutes (Überall and Müller-Schwefe 2011). N-dealkylation is the major 
route of fentanyl metabolism to norfentanyl (Labroo et al. 1997). Norfentanyl has 
been recovered in plasma and in urine.  
Transmucosal fentanyl has also been evaluated as a premedication in patients 
undergoing surgery in general anaesthesia and patients having bone marrow 
aspiration and biopsy. It was found to be effective in decreasing anxiety before 
general anaesthesia (Singh, Choubey, and Mehra 2017)  but it did not reduce the pain 
during bone marrow aspiration and biopsy (Kuivalainen, Ebeling, and Rosenberg 
2013). 
2.2 Drug-drug interactions associated with 
buprenorphine 
2.2.1 Cytochrome P450 (CYP) enzymes 
The family of CYP enzymes has a significant role in drug metabolism. CYP-
enzymes are predominantly located in liver, but also in intestine, lungs and other 
organs. There are at least 30 different CYP-enzymes which have been identified 
(Dresser, Spence, and Bailey 2000) and these enzymes are responsible for the 
oxidative biotransformation of drugs. CYP3A4 metabolizes the greatest number of 
drugs and together with CYP2D6, CYP2B6, CYP2C9, CYP2C19 and CYP2D6 they 
are responsible for more than 90% of known oxidative drug metabolism reactions 
(Pelkonen et al. 2008; Wienkers and Heath 2005). DDI studies have focused on drugs 
that are substrates, inhibitors or inducers of CYP enzymes because the inhibition or 
induction of CYP enzymes is the main reason for numerous DDIs (Michalets 1998). 
Most drugs are metabolized through several CYP forms and drugs that are 
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metabolized by a single CYP form are more susceptible to drug interactions 
(Pelkonen et al. 2008). 
Enzyme inhibition is usually reversible and it can be divided into competitive, 
non-competitive, uncompetitive and mixed-type inhibition. Inhibition is competitive 
when substrate and inhibitor bind to the same position of the enzyme. The active 
binding site of substrate and inhibitor differ from each other in the non-competitive 
mode of inhibition. When inhibition is uncompetitive, the inhibitor binds to the 
enzyme-substrate complex, but not to the free enzyme entity. Both competitive and 
non-competitive inhibition are observed in mixed-type inhibition. (Pelkonen et al. 
2008). 
Induction is another type of drug interaction, where drug stimulates excess 
production of a CYP isoenzyme and the result is increased metabolism of a second 
agent (DuBuske 2005). This can lead to decreased plasma concentrations and 
reduced efficacy.  
N-dealkylation, the main metabolic pathway of buprenorphine is catalysed 
mainly by CYP3A4 (Iribarne et al. 1997; Kobayashi et al. 1998). In fact, 
buprenorphine itself has been found to inhibit CYP3A4 and CYP2D6 in vitro, but 
with therapeutic concentrations of buprenorphine there are no significant 
interactions with other CYP-metabolized drugs to be expected (Umehara, 
Shimokawa, and Miyamoto 2002; Zhang et al. 2003). However, it can be presumed 
that the concomitant use of buprenorphine with drugs which are inducers or 
inhibitors of CYP3A4 enzyme would lead to an altered pharmacokinetic profile of 
buprenorphine.  
There are some studies where DDIs of high-dose buprenorphine and HIV 
protease inhibitors have been evaluated. These studies have shown that atazanavir 
alone and with ritonavir increase the concentrations of buprenorphine and its 
metabolites in plasma (McCance-Katz et al. 2007). In that study, the authors 
discussed the possible mechanisms for the increased concentrations of 
buprenorphine and its metabolites. The most straightforward explanation would be 
an increased bioavailability of the drug when first-pass metabolism was blocked but 
it was also possible that the increased concentration of metabolites of buprenorphine 
might reflect a diversion of buprenorphine metabolism from dealkylation to 
glucuronidation via inhibition of CYP3A4. Indinavir is also a potent inhibitor of 
buprenorphine N-dealkylation. Saquinavir has been studied in vitro, but it was 
weaker competitive inhibitor and it was claimed that it probably would not inhibit 
buprenorphine in vivo (Iribarne et al. 1998). 
Some in vitro studies have shown that ketoconazole, a recognized CYP3A4 
inhibitor, is a potent inhibitor of buprenorphine N-dealkylation (Cowan 2003). 
According to the product monograph of Suboxone® (Suboxone Summary of Product 
Characteristics), the daily administration of ketoconazole during buprenorphine 
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maintenance treatment leads to an increase of the Cmax and AUC of buprenorphine 
in plasma. Another study explored the effect of ketoconazole on the 
pharmacokinetics of transdermally administered buprenorphine. They found no 
significant DDI between ketoconazole and transdermal buprenorphine and the 
explanation for this finding was assumed to be the lack of pre-systemic metabolism 
when buprenorphine is administered transdermally (Kapil et al. 2012).  
It is estimated that among the opioid users and patients in maintenance treatment 
psychiatric disorders are very common (Regier et al. 1998). However, there are no 
clinical interaction studies made with drugs used to treat these disorders. There is 
only one report in the literature; this is an  in vitro study with fluoxetine and it showed 
that fluoxetine-induced CYP2D6 inhibition would be unlikely to significantly affect 
the metabolism of  buprenorphine in vivo (Iribarne et al. 1998).  
The concomitant use of benzodiazepines and buprenorphine has been reported 
to lead to serious, sometimes even fatal, interactions, (Reynaud et al. 1998). 
Benzodiazepines are not considered to be CYP3A4 inhibitors, although some of 
them are substrates for this enzyme (Saari et al. 2006; 2008). As stated, it has also 
been predicted that buprenorphine does not significantly inhibit CYP3A4 (Umehara, 
Shimokawa, and Miyamoto 2002). These interactions are thus more likely to be 
pharmacodynamic in their nature resulting from respiratory depression. 
The first clinical interaction study where withdrawal symptoms were found 
among the patients using high-dose buprenorphine was published in 2011 
(McCance-Katz et al. 2011). In that study, rifampicin was administered orally with 
a clinically used dose for 15 days. Rifampicin decreased the concentration of 
sublingual buprenorphine significantly and caused withdrawal symptoms to patients. 
Rifabutin was also studied with the same method and it was found to decrease the 
concentrations of buprenorphine as well, but the effect was milder than after 
rifampicin and did not cause withdrawal symptoms in the patients.  
2.2.2 P-glycoprotein 
It is well known that CYP enzymes play a major role in drug metabolism and 
pharmacokinetic drug interactions. However, there are some interactions that cannot 
be explained exclusively by the inhibition or the induction of the CYP enzymes and 
it has become apparent that additional mechanisms, e.g. those involving membrane 
transporter proteins, are also involved in many interactions. P-gp is one of the drug 
transporter systems, which is thought to participate in some DDIs and DFIs. P-gp is 
an energy dependent transmembrane efflux protein driven by ATP hydrolysis. It is 
found in many tissues throughout the body and it is responsible for the transport of 
many drugs (Ayrton and Morgan 2001). For example, it has been found to be one of 
the several transmembrane efflux transporter proteins in the blood brain barrier. The 
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absorption, distribution, and excretion of drugs can be altered when active drug 
transporter systems are inhibited or induced. Many drugs and foods that affect CYP 
enzymes have also an effect on P-gp (Lin 2003; Yasuda et al. 2002). For example, 
while rifampicin is known to be a strong inducer of CYP3A4, it also enhances the 
activity of P-gp (Greiner et al. 1999; Niemi et al. 2003).  When drug metabolism is 
not extensive, transporter proteins probably play the primary role in the absorption 
and excretion of various substances. P-gp is found in high levels in the small and 
large intestine, in the luminal membranes of renal proximal tubules and in the biliary 
canalicular membrane of hepatocytes. The presence of P-gp in these tissues suggest 
that it facilitates excretion of substances into urine, bile and into the intestinal lumen 
(DuBuske 2005). The normal transport function of P-gp may be interfered by other 
drugs and this can lead to clinically significant alteration in serum drug 
concentrations.  
Several opioids are known to be substrates of P-gp, including morphine, 
methadone and fentanyl (Dagenais, Graff, and Pollack 2004). The role of P-gp in the 
transport of buprenorphine is not clear. In vitro studies in rodents suggest that 
norbuprenorphine, but not buprenorphine, is a substrate of P-gp (Hassan et al. 2009; 
Brown et al. 2012).  
2.2.3 UGTs 
UDP-glucuronosyl transferases (UGTs)  play a significant role in the second 
metabolic pathways of 20-30 % of the currently marketed drugs (Stingl et al. 2014).  
After the CYP enzymes UGTs hold the second place as the primary metabolic 
pathway  (Wienkers and Heath 2005; Williams et al. 2004). Buprenorphine and 
norbuprenorphine undergo glucuronidation by UGTs to B3G and N3G (Bruce et al., 
2006). UGT2B7 is responsible for more than 40% of buprenorphine glucuronidation 
while norbuprenorphine glucuronidation is mainly mediated by UGT1A3 (Rouguieg 
et al. 2010). Glucuronidation is considered as a detoxification and inactivation 
pathway but in a recent study both B3G and N3G were found to have receptor 
binding and pharmacological activity (Brown et al. 2011). In a recent study the 
possibility to increase oral bioavailability of buprenorphine by inhibiting UGT 
enzymes was examined (Maharao, Venitz, and Gerk 2019). In this study, the authors 
found that with the concomitant use of dietary compounds, that are known to inhibit 
buprenorphine metabolism by inhibiting UGTs, it was possible to achieve higher and 
less variable bioavailability of orally administered buprenorphine. The UGTs are 
also induced and inhibited by the same drugs that affect the activity of CYP enzymes. 
Rifampicin is known to induce the activity of UGTs (Niemi et al. 2003) and 
according to semi-physiological population pharmacokinetic model voriconazole is 
a UGT2B inhibitor in the gut and liver (Frechen et al. 2013). It is assumed that 
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inhibition of one metabolic route might cause a diversion to other routes and if 
metabolites are pharmacologically active the clinical effect of the drug may be 
significantly altered.  
2.3 CYP inhibitors 
2.3.1 Voriconazole 
Voriconazole is a second generation triazole antimycotic, a derivative of 
fluconazole. It has been in clinical use since 2001. Voriconazole has a very broad 
spectrum of antifungal activity and it has become the first-line drug for the treatment 
of invasive aspergillosis (Boucher et al. 2004). It has also been approved for 
treatment of candicemia in non-neutropenic patients. However, there are increased 
number of reports of voriconazole resistance in invasive aspergillosis (Resendiz-
Sharpe et al. 2019). 
Voriconazole has a high oral bioavailability of over 90 % after oral 
administration, and it is absorbed rapidly within 2 hours (Purkins et al. 2003). Food 
delays absorption significantly and therefore voriconazole should be taken in an 
empty stomach (Purkins et al. 2003). Steady-state concentrations are reached in 5-7 
days when voriconazole is administered orally. By using a loading dose, the time to 
steady-state can be reduced to 1-2 days. There is extensive variability in 
concentrations of voriconazole and this can be due to CYP2C19 polymorphism 
(Purkins et al. 2003). 
Plasma protein binding of voriconazole is independent of the plasma 
concentration and the binding rate is found to be 58%. Voriconazole has been shown 
to penetrate in many tissues, such as the lungs and the central nervous system 
(Lutsar, Roffey, and Troke 2003; Capitano et al. 2006). Cerebrospinal fluid 
concentrations of voriconazole are found to be 50% of plasma concentrations and 
even higher in brain tissue.  
Voriconazole is distributed widely to tissues and its volume of distribution is 
approximately 4.6 L/kg. The mean elimination half-life of voriconazole is 6 hours 
after steady-state is achieved (Jeu et al. 2003). 
There is a broad range of drug-drug interactions which influence significantly 
serum concentrations of voriconazole. Voriconazole is a substrate for P450 
isoenzymes and therefore many drug-drug interactions must be considered. 
Voriconazole has a narrow therapeutic index and it displays non-linear 
pharmacokinetics. Co-administration of voriconazole with other drugs that are 
substrates of the CYP metabolic enzymes may lead to clinically relevant toxicity if 
the therapeutic index of the drug is narrow. Voriconazole is known to be a 
competitive inhibitor of many CYP enzymes and this inhibition has been detected in 
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several drug-drug interaction studies (Saari et al. 2007; Hagelberg et al. 2009; Saari 
et al. 2008).  
The most common adverse effect of voriconazole is visual disturbances and it 
has been reported that almost 30 % of patients experienced a change in colour vision 
and blurred vision and this typically lasted 30 minutes and resolved spontaneously. 
Elevations in liver function markers and skin reactions have also been reported to be 
quite common adverse effects during voriconazole therapy (Jeu et al. 2003; Denning 
et al. 2002). 
2.3.2 Posaconazole 
Posaconazole was approved for clinical use in September 2006 and it was developed 
for prophylaxis and treatment of fungal infections in immunocompromised 
individuals such as patients with hematologic malignancies and allogenic stem stell 
transplant recipients. Posaconazole has been found to be more effective than 
fluconazole (Ullmann et al. 2007) and it improves the overall survival in patients 
with acute leukemia or myelodysplastic syndrome patients undergoing intensive 
chemotherapy (Cornely et al. 2007). Delayed release tablets of posaconazole were 
released for clinical use in November 2013 and an intravenous formulation for the 
treatment of invasive aspergillosis in March 2014.  
The relative bioavailability of oral posaconazole has been observed to be 
significantly increased when the daily dose is divided into several smaller doses. The 
relative bioavailabity was increased by 98% when administered as two different 
doses 12 hours apart comparing to single dose administration (Ezzet et al. 2005). In 
addition, concomitant food intake with posaconazole increases the bioavailability of 
posaconazole significantly (Courtney et al. 2004) and whenever possible 
posaconazole should be administered with a full meal. The maximum plasma 
concentration of posaconazole is reached in 5-8 hours following single dose 
administration (Courtney et al. 2003). Different studies report the median tmax to be 
3-6 hours and it takes 10 days to reach steady-state concentrations with oral twice-
daily dosing (Courtney et al. 2003; 2004; Ezzet et al. 2005). 
Posaconazole undergoes a very extensive degree of binding to plasma proteins 
(>98%) and the binding is independent of concentration. The values for volume of 
distribution at steady-state have ranged from 5L/kg to 25L/kg (Courtney et al. 2003; 
Krieter et al. 2004). This suggests extensive penetration into intracellular spaces. 
However, posaconazole is found to penetrate poorly into cerebrospinal fluid because 
of its high degree of protein binding (Perfect et al. 1996). 
CYP enzymes do not participate significantly in the metabolism of posaconazole. 
Posaconazole is primarily an inhibitor of CYP3A4 and does not have an effect on 
the other studied CYP isoenzymes (1A2, 2C8, 2C9, 2D6 and 2E1) (Wexler et al. 
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2004). Posaconazole passes into plasma after absorbtion and then it is widely 
distributed to the tissues and thus slowly eliminated. It has been found that UGTs 
are responsible for most of the metabolism of posaconazole (Ghosal et al. 2004).  
2.4 CYP inducer 
2.4.1 Rifampicin 
Rifampicin was discovered in 1965. It was first clinically used in Italy in 1968 and  
it was approved in the USA in 1971. Rifampicin was introduced as a part of 
combination therapy for tuberculosis and it shortened the duration of treatment from 
18 to 9 months (Zumla, Nahid, and Cole 2013). Rifampicin is mainly bacteriocidal 
antibiotic and its effect is based on the inhibition of the bacterial DNA-dependent 
RNA polymerase activity (Campbell et al. 2001). In addition to the treatment of 
tuberculosis, rifampicin is often used in the treatment of staphylococcus infections 
(Turnidge and Grayson, 1993).The optimal dosage of rifampicin has not been 
definitely established and the current recommendation from the guideline of the 
WHO is still the same as it was at the time of the introduction of rifampicin (Van 
Ingen et al. 2011). Rifampicin has a very wide spectrum, but because of high 
amounts of resistant bacterial strains it is often used as a combination with other 
antibacterial agents.  
When administered on an empty stomach rifampicin is almost completely 
absorbed (Acocella 1978). The peak plasma concentration of rifampicin after single 
oral dose is achieved in 2 hours. Rifampicin has a high degree of binding to plasma 
proteins (~80%). High concentrations of rifampicin have been detected in various 
tissues, such as cerebrospinal fluid. The strong induction of CYP3A4 by  rifampicin 
has been detected one day after the first administration of the drug. 
Rifampicin is mainly excreted into bile by liver but also into urine by kidneys. 
The main metabolite of rifampicin is desacetylrifampicin, which is an active but 
weaker antimicrobial agent than the parent drug (Acocella 1978). The elimination 
half-life  of rifampicin can be shortened to 2-3 hours due to its significant 
autoinductive effect (Loos and Musch, 1985). Severe adverse effects during 
rifampicin treatment are rare, but urine, feaces, saliva, tears and sweat may be 
colored reddish. This is a reversible effect and disappears after discontinuation of 
medication.  
Many clinically relevant interactions of rifampicin have been reported in the 
literature (Saarikoski et al. 2013; Backman et al. 1998). Rifampicin is known to be 
one of the strongest inducers of orally administered substrates of CYP3A4 and P-
glycoprotein. This can even lead to a total loss of effect of some drugs if they are 
taken in combination with rifampicin (Villikka et al. 1997). It has also been shown 
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that the oral bioavailability of digoxin, a substrate of P-gp, was significantly reduced 
after concomitant rifampicin administration in healthy subjects (Greiner et al. 1999). 
Rifampicin induces also other CYP enzymes such as CYP1A2, CYP2A6, CYP2B6, 
CYP2C9, CYP2C19 and CYP3A5(Niemi et al. 2003). 
2.5 Colonoscopy 
2.5.1 Pain during colonoscopy 
Colonoscopy is considered as an uncomfortable and often painful procedure for the 
patient. The cause of pain during colonoscopy is mainly due to the stretching of the 
mesenteric attachments. The minor cause for pain is the pressure of air distension 
(Waye 2002). Several studies have found female gender, younger age, lower BMI, 
irritable bowel, anxiety and anticipated discomfort and technically difficult insertion 
to be independent factors related to the patient’s discomfort during colonoscopy 
(Elphick et al. 2009; Park et al. 2007). The poor quality of bowel preparation and a 
less experienced colonoscopist have been associated to reduced completion rate and 
increased ceacal intubation time (Cirocco and Rusin, 1995). A history of gynaeco-
pelvic surgery has also been related to higher discomfort during colonoscopy (Park 
et al. 2007).  
The reliable assessment of pain is difficult because pain is such a subjective, 
personal and private experience. However, a valid assessment of pain is essential for 
effective pain management and for successful clinical trials. There are some well-
known scales for the assessment of pain intensity. Both visual analogue (VAS) and 
numerical rating scales (NRS) have been found to be valid (Jensen, Miller, and 
Fisher 1998; Ferreira-Valente, Pais-Ribeiro, and Jensen 2011) and superior to a four 
point verbal categorical rating scale (VRS) (Breivik, Björnsson, and Skovlund 
2000). When assessing postoperative pain, the NRS and VAS have been shown to 
give almost identical values in the same patient. There are some studies though that 
seem to indicate that NRS may be slightly more sensitive than VAS (Ferreira-
Valente, Pais-Ribeiro, and Jensen 2011). Furthermore, a NRS with numbers starting 
from 0 and ending at 10 is thought to be more practical and easier to understand for 
most people than VAS. NRS is easier to use and no clear vision, paper or pen are 
needed. NRS can also be used during a telephone interview (Breivik et al. 2008). 
When pain is assessed with the NRS scale, no pain is defined as 0, mild pain as 1-3, 
moderate pain as 4-6, severe pain as 7-9 and the worst pain imaginable as 10 (Fig 2).  
Colonoscopy was developed to be a non-sedated procedure. However, 
procedural difficulties, pain and uncomfortable experiences by patients have led to 
the introduction of sedation prior to colonoscopy. Non-sedated colonoscopy has 
acquired a negative popular image (Leo 2004). However, there are many ways other 
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than medicinal sedation to make this procedure more comfortable and less painful 
for the patient. By using a small-calibre colonoscope the mean pain scores were 
found to be significantly lower during the procedure (Sato et al. 2013). 
Transcutaneous electrical nerve stimulation (TENS) has been reported to be effective 
in relieving pain during colonoscopy (Amer-Cuenca et al. 2011). It has also been 
shown that using water instead of air in ceacal intubation reduces the need of sedation 
and the degree of pain (Lin et al. 2013). Several studies also suggest that listening to 
music during colonoscopy can relieve the patient's anxiety and pain (Ko, Leung, and 
Wong 2019;  Ko et al. 2017). 
 
Figure 2.  Numerical rating scale 0-10 for pain. 
2.5.2 Sedation and analgesia 
By applying sedation to colonoscopy it is possible to minimize the discomfort and 
pain experienced by the patient (Vargo et al. 2002; Terruzzi et al. 2001). At its best, 
sedation can facilitate the work of the endoscopist and decrease the duration of 
procedure. However, the risk of cardiorespiratory complications is increased when 
sedation is used (Ristikankare et al. 2000; Rex, Imperiale, and Portish 1999). 
Sedation also increases the costs of colonoscopy because of the need of monitoring, 
more staff as well as longer recovery time (M. Ristikankare et al. 1999; Rex, 
Imperiale, and Portish 1999). Most of the colonoscopies are performed as outpatient 
procedures and thus the sedation used must ensure safety but also allow rapid 
recovery of patients.  
Definitions for different levels of sedations have been published by American 
Society of Anesthesiology (ASA) (Early et al. 2018). The sedation levels are divided 
into minimal, moderate and deep sedation. Moderate sedation, also called conscious 
sedation, is the most commonly used level of sedation and it is usually induced by 
the combination of midazolam and fentanyl. At the level of moderate sedation, the 
patient maintains ventilatory and cardiovascular function and can respond to verbal 
stimuli adequately.  
There are remarkable differences in sedation practices between countries. In 
some European countries most of the colonoscopies are done without sedation 
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(Froehlich et al. 2006) while in the USA and UK, sedation is used in almost all 
colonoscopies (Bowles et al. 2004; Cohen, Wecsler, and Gaetano 2006). These 
differences are explained by cultural considerations, patient attitudes and 
expectations, budgets and resources (Terruzzi et al. 2001). A large multicentre 
European survey on sedation practices for colonoscopy reported that from 6000 
colonoscopy cases 53 % received moderate sedation, 30 % deep sedation and 17 % 
without sedation (Froehlich et al. 2006). 
The most commonly used drugs for sedation are midazolam and opioids, usually 
fentanyl or pethidine, or a combination of these agents (Froehlich et al., 2005). It has 
been shown that with relatively small doses of fentanyl or alfentanil combined with 
midazolam adequate sedo-analgesia and high patient satisfaction can be achieved 
(Usta et al. 2011). It has also been suggested that sedation improves the overall 
quality of colonoscopy (Salvador Baudet and Aguirre-Jaime 2019). On the other 
hand, routinely administering midazolam sedation did not increase patient tolerance 
nor did it make colonoscopy technically easier in a previous Finnish study 
(Ristikankare et al. 1999). There are a few studies where opioid alone has been used 
during colonoscopy but more commonly the opioid has been combined with 
midazolam or propofol. However, in one study a small dose of intravenous fentanyl 
was found to provide adequate pain relief during colonoscopy (Lazaraki et al. 2007). 
Nitrous oxide has also been reported to be effective for pain relief during 
colonoscopy,  it is even thought to provide better pain relief and faster recovery than 
the midazolam-fentanyl combination (Maslekar et al. 2009; Wootton 1998). 
A recent meta-analysis suggested that propofol would be superior to traditional 
sedative agents. Recovery and discharge times were shorter and the satisfaction score 
was greater than with benzodiazepines (Zhang, Zhu, and Zheng 2018). However, 
propofol sedation is associated with longer recovery times as compared with sedation 
with midazolam and fentanyl in  elderly patients (Lovett et al. 2017). The use of 
propofol doses that provide deep sedation might predispose patients to an increased 
risk of perforation (Adeyemo et al. 2014). 
Dexmedetomidine is a rather new sedative agent which has minimal adverse 
effects on respiratory function. It has been shown that dexmedetomidine sedation 
during colonoscopy achieves higher satisfaction and lower NRS scores than 
midazolam (Dere et al. 2010). Dexmedetomidine has also been compared to small 
doses of intravenous fentanyl and there were no differences in either patient or 
colonoscopist  satisfaction with the procedure nor in the duration of colonoscopy, 
but mean pain score during colonoscopy was lower when dexmedetomidine was 
used (Amri et al. 2018). However, there are many studies that advocate that 
colonoscopy can be successfully completed without sedation (Leung 2011; Ylinen 
et al. 2009; Ristikankare et al. 1999; Iqbal et al. 2016).  
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2.5.3 Recovery after procedure 
Sedation during colonoscopy increases the costs and the time spent in the procedure. 
Non-sedated colonoscopy naturally offers the possibility to discharge the patient 
immediately after the procedure and the patient is able to leave without requiring an 
escort and to drive home. There is a group of patients who value the possibility to 
return to their daily activities as quickly as possible (Subramanian, Liangpunsakul, 
and Rex 2005). However, the majority of the patients undergoing colonoscopy prefer 
sedation during the procedure. Ideal sedation should provide good analgesia and 
relief of discomfort, but the drug effect should be short and should not cause mental 
or psychomotor impairment after the end of the procedure.  
Most often sedation is carried out with low-dose midazolam alone or combined 
with an opioid. Sarasin et al. reported that midazolam and propofol caused an 
equivalent impairment of cognition and psychomotor functions, but the duration of 
the effect of midazolam was longer (Sarasin, Ghoneim, and Block 1996). When 
compared to midazolam, dexmedetomidine was found to provide better sedation and 
lower pain scores but there were no differences between the groups when comparing 
recovery times (Dere et al. 2010). Patient-controlled nitrous oxide has been claimed 
to be effective during colonoscopy and it allowed a faster recovery compared to 
midazolam-fentanyl sedation (Maslekar et al. 2009). The mean time to discharge was 
28 minutes in the nitrous oxide group and 51 minutes in the midazolam fentanyl 
group and the recovery of function at discharge was found to be 100 % in nitrous 
oxide group and 87.3 % in midazolam-fentanyl group.  
It has been reported that single use of intravenous fentanyl in colonoscopy was 
effective and could significantly shorten recovery times (Lazaraki et al. 2007). 
Patients received either a mean dose of 4.6 mg of intravenous midazolam or 36 µg 
of intravenous fentanyl. The mean recovery time was 5.6 minutes in the fentanyl 
group and 16 minutes in the midazolam group. To the best of our knowledge, there 
are no studies where other than intravenous formulation of fentanyl has been 
evaluated in patients undergoing colonoscopy. 
Propofol was found to offer a faster and more predictable recovery in meta-
analysis of 36 randomized studies (McQuaid and Laine 2008). In another meta-
analysis of 22 randomized controlled trials propofol was associated with both shorter 
recovery and discharge times (Wang et al. 2013). A recently conducted meta-
analysis suggested that propofol would be  superior to traditional sedative agents in 
the terms of shorter recovery and discharge times (Zhang, Zhu, and Zheng 2018). 
However, in the elderly patient population propofol was reported to prolong the 
recovery time compared to a combination of midazolam and fentanyl (Lovett et al. 
2017). The mean recovery time was estimated to be 50 minutes in the propofol group 
as compared to 31 minutes in patients administered both midazolam and fentanyl. 
Poulos et al. also compared propofol and midazolam-fentanyl sedations but the result 
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was opposite, recovery in the propofol group was shorter (Poulos et al. 2013). The 
patients in this latter study were relatively young, the mean age of the cohort was 56 
to 57 years. Propofol has also been used for procedural sedation in the combination 
with short acting opioids. Interestingly, propofol combined with alfentanil was found 
to cause less cognitive dysfunction than propofol alone or when combined with 
fentanyl (Doǧanay et al. 2017). There was no difference in patient satisfaction 
between the groups. The median propofol consumption was 150 mg in the alfentanil 
group, 100 mg in the fentanyl group and 230 mg in the propofol group, respectively. 
Alfentanil combined with midazolam was also reported to provide shorter sedation 
than fentanyl combined with midazolam (Usta et al. 2011). Borrat et al. used 
computerized tests to evaluate the recovery of cognitive function after deep propofol 
and remifentanil sedation (Borrat et al. 2019). They found that cognitive function 
had completely recovered in all patients 40 minutes after propofol and remifentanil 
infusions.  
2.5.4 Patient satisfaction 
Patient comfort during the colonoscopy procedure is important for patient 
satisfaction (Maslekar et al. 2010) and willingness to undergo a repeat examination 
if needed (Hoffman, Butler, and Shaver 1998). The assessment of comfort is, 
however, as complex as the assessment of pain because the experience is subjective 
and patients’ expectations and tolerance differ. In a recent study significant 
discomfort was associated with longer colonoscope insertion times and longer 
colonoscope withdrawal times  (Ball et al. 2015). Interestingly, in that study, patients 
receiving no sedation were least likely to feel significant discomfort. It has also been 
indicated in other reports, that routinely administered low-dose midazolam does not 
relieve the discomfort during colonoscopy (Elphick et al. 2009; Ristikankare et al. 
1999). In a study where intravenous dexmedetomidine and  intravenous fentanyl 
were compared for sedation during colonoscopy, although the mean pain score was 
lower in the dexmedetomidine group, there were no significant differences in the 
patients’ satisfaction between the groups  (Amri et al. 2018). When compared to 
midazolam, higher satisfaction scores were obtained with the application of 
dexmedetomidine (Dere et al. 2010). There are not many studies where an opioid 
has been used as a single drug for sedation. Lazaraki et al. reported that a small dose 
of intravenous fentanyl produced significantly lower discomfort scores than obtained 
with intravenous midazolam alone (Lazaraki et al. 2007). In the fentanyl group the 
mean discomfort score was 0.4 whereas it was 1.0 in the midazolam group.  
There are countries, where most of the colonoscopies are done without sedation. 
In Germany, sedation is used in only 5% of colonoscopies (Froehlich et al. 2006). 
There is no recent data about sedation practices in Finland, but 20 years ago,  most 
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colonoscopies were performed without sedation (Ristikankare and Julkunen 1998). 
However, globally most patients prefer sedation during colonoscopy. Subramanian 
et al. used a questionnaire to reveal the pre-procedure patient values regarding 
sedation use for colonoscopy (Subramanian, Liangpunsakul, and Rex 2005). A total 
of 210 American patients participating in that study placed the highest valuation on 
experiencing no pain during procedure, waking up promptly after the procedure and 
for going to sleep and not waking until the procedure was over. There was a small 
group of patients, 6.2 % of the participating subjects, who preferred colonoscopy 
without sedation. Norwegian group assessed patient satisfaction with on-demand 
sedation and they also wanted to identify factors related to moderately or severely 
painful colonoscopy (Seip et al. 2010). They gathered 12354 patient reports from 
nine endoscopy centres. The mean rate of painful colonoscopies was 34% and 
sedation had been used on average in 34% of colonoscopies. However, high sedation 
rates were not associated with low rates of painful colonoscopies. Patient satisfaction 
with service and information given was greater than 95% for all centres.  
Several meta-analyses have shown that when sedation is implemented with 
propofol significantly higher satisfaction scores are achieved compared to traditional 
sedation with midazolam and opioid (Zhang, Zhu, and Zheng 2018; Wang et al. 
2013; McQuaid and Laine 2008). High patient satisfaction has also been associated 
with the  use of nitrous oxide (Maslekar et al. 2009) and patient controlled analgesia 
(Külling et al. 2004; Usta et al. 2011). Both are considered safe and effective during 
colonoscopy. It is also possible to achieve good patient satisfaction without sedation; 
there are several non-medical methods, such as hypnosis, music, TENS and the use 
of a small calibre colonoscope, which may reduce the amount of discomfort and 
increase patient satisfaction during colonoscopy (Leung 2008).  
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3 Aims of the Study 
New dosage forms of buprenorphine have increased the use of low-dose 
buprenorphine in the treatment of chronic pain. High doses of buprenorphine are 
used to treat opioid dependence and some interaction studies of high-dose 
buprenorphine have been conducted. However, currently the literature holds very 
little information about interactions occurring with low dose buprenorphine.  
Colonoscopy is considered an unpleasant and painful procedure. Traditionally, 
colonoscopies have been performed without sedation in Finland, but globally, most 
patients prefer sedation. Intravenous sedation increases the costs and length of the 
procedure. Sublingually administered fentanyl is a non-invasive method capable of 
relieving pain and making the procedure more comfortable for the patient. Compared 
to intravenous sedation, the sublingual administration route could be more cost-
effective and easier to implement. 
 
The specific aims for these studies were: 
1. To study the possible effects of voriconazole and posaconazole on the 
pharmacokinetics and pharmacodynamics of sublingual buprenorphine 
(Study I) 
2. To determine the possible effect of voriconazole on the pharmacokinetics 
and pharmacodynamics of oral buprenorphine (Study II) 
3. To evaluate the effect of rifampicin on the pharmacokinetics of sublingual 
and intravenous buprenorphine (Study III) 
4. To examine how the route of buprenorphine administration affects the 
pharmacokinetic interactions of buprenorphine (Studies I-III) 
5. To evaluate the efficacy and safety of sublingually administered fentanyl 
tablet in patients undergoing colonoscopy (Study IV) 
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4 Materials and Methods 
4.1 Interaction studies 
4.1.1 Subjects  
Altogether 36 healthy male and female volunteers participated in interaction studies 
I-III.  The demographic details of subjects are shown in Table 1.  
We recruited 12 healthy non-smoking volunteers into each of three studies. 
Recruitment was carried out by emails directed to university students. If subjects 
were interested in the study, they contacted the investigator by phone or email and 
received more information about the study. If they still were interested to participate, 
they were invited to attend a personal visit.  
Table 1.  Characteristics of volunteers (mean (range)) in Studies I-III. 
 
Sex F/M 
Age years 
(range) 
Weight kg 
(range) 
BMI kg/m2 
(range) 
I 4/8 20 (19-23) 67(52-81) 22 (20-25) 
II 4/8 22 (18-29) 71 (57-90) 23 (21-28) 
III 6/6 21 (19-23) 73 (57-95) 23 (19-26) 
F = female; M = male; BMI = body mass index 
During the personal visit volunteers were informed about the details of the study 
protocol. Clinical examination including blood pressure in the sitting position and 
routine laboratory tests including complete blood count (hemoglobin, hematocrit, 
differential white blood cell count and platelet count), serum aspartate 
aminotransferase, alanine transferase, alkaline phosphatase, blood urea nitrogen and 
creatinine and urine tests for glucose, proteins, drugs with addiction potential 
(amphetamine, cannabis, cocaine, opioids, phencyclidine, methadone, 
dextropropoxifen and benzodiazepines), were performed to evaluate the 
participants’ physical health. Their medical history was also obtained and all 
participants were found to be in good physical health. Urine toxicology and 
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pregnancy tests were negative and ECGs were within normal limits. The Finnish 
translation of the Abuse Questions (Table 2) (Michna et al. 2004) was used to 
evaluate the risk of participants to develop opioid abuse and the risk was found to be 
low for every participant. Volunteers were not allowed to drink coffee, tea, energy 
drinks or grapefruit juice for 4 weeks prior to and during the study. Female 
participants were given instructions to use safe non-hormonal contraception during 
the study because hormonal contraceptives were not allowed. All subjects gave their 
written informed consent and the subjects were given instructions on how to perform 
the pharmacodynamic tests.   
 The exclusion criteria included concomitant drug therapy, previous history of 
intolerance to any of the drugs studied, past history of significant disease, 
alcoholism, drug abuse or psychological or emotional problems, blood donation 
within 4 weeks prior to the study, and participation in any other studies involving 
drug products within one month prior to the current study.  
Table 2.  Abuse Questions by Michna 2004 (Michna et al. 2004). 
1. Is there a history of alcohol or substance abuse in your family, even among your 
grandparents, aunts, or uncles? 
2. Have you ever had a problem with drugs or alcohol or attended an Alcoholics Anonymous 
or Narcotics Anonymous meeting? 
3. Have you ever had any legal problems or been charged with driving while intoxicated or 
driving while influence? 
4.1.2 Study design 
The data was collected between March 2011 and February 2014. All three studies 
were carried out using a randomized, balanced, placebo-controlled, cross-over 
design. Study I consisted of three phases, Study II consisted of two phases and four 
phases were used in Study III. There was a four weeks’ drug-free period in all studies 
between the phases.  
Pre-treatment in Studies I-III 
The investigator distributed the research medicines and placebos to volunteers and 
instructed them to take the pre-treatment at home according to the protocol. Study 
drugs and placebos were packed in identical plastic containers by a hospital 
pharmacist who was not involved in the study. Posaconazole was delivered in its 
original container, but the drug label was removed. The hospital pharmacist 
delivered the drugs and placebos according to a randomization list. The numbers of 
drug tablets or placebo capsules per day during the pre-treatment phases were 
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similar.  Adherence with the medicine/placebo dosing schedule was assessed using 
mobile phone text messages. After taking each dose, the subjects sent a mobile phone 
text message to one of the investigators. The investigator contacted the subject if no 
text message was received within 15-20 min after the scheduled dosing time and 
reminded him/her to take the dose. Voriconazole and posaconazole concentrations 
were determined in Study I and voriconazole concentrations in Study II. The dosing 
schedule of the pre-treatments is shown in Table 3. 
In Study I the volunteers ingested orally voriconazole (Vfend 200 mg tablet; 
Pfizer, Sandwich, Great Britain), posaconazole (Noxafil 40 mg/ml oral suspension; 
Merck Sharp & Dohme, Hoddesdon, Great Britain) or placebo for 5 days twice daily. 
In Study II voriconazole (Vfend 200 mg tablet; Pfizer, Sandwich, Great Britain) or 
placebo were administered orally for 5 days twice daily. The pre-treatment used in 
Study III was either oral rifampicin (Rimapen 600 mg® tabl, Orion, Finland) or 
placebo once daily for seven days in a randomized order. 
Table 3.  Design of studies I-III. 
 
Study 
Pre-treatment Buprenorphine 
CYP3A4 inhibitor or inducer Dosing schedule Dosing schedule 
I 
Phase 1 Voriconazole 200 mg 
tabl 
 
 
 
 
Phase 2 Posaconazole oral 
suspension 40 mg/ml 
Phase 3 Placebo caps  
2 tabls at 8 A.M and 8 P.M on 
day 1 
1 tabl at 8 A.M. and 8 P.M. on 
day 2-4  
1 tabl 10 A.M. and 8 P.M. on 
day 5 
10 ml at 8 A.M. and 8 P.M. on 
day 1-4 
10 ml 10 A.M. and 8 P.M. on 
day 5 
0.4 mg SL at 11 A.M. on day 5 
 
 
 
 
 
0.6 mg SL at 11A.M. on day 5 
(placebo phase) 
II 
Phase 1 Voriconazole 200 mg 
tabl 
Phase 2 Placebo caps 
2 tabls at 8 A.M and 8 P.M on 
day 1 
1 tabl at 8 A.M. and 8 P.M. on 
day 2-4  
1 tabl 10 A.M. and 8 P.M. on 
day 5 
0.2 mg P.O. at 11 A.M. on day 5 
 
3.6 mg P.O. at A.M. on day 5 
(placebo phase) 
III 
Sublingual part 
Phase 1 Rifampicin 600mg tabl 
Phase 2 Placebo caps 
 
Intravenous part 
Phase 3 Rifampicin 600mg tabl 
Phase 4 Placebo caps   
 
1 tabl at 8 P.M. for 7 days  
 
 
 
1 tabl at 8 P.M. for 7 days  
 
0.8 mg SL at 11 A.M. on day 7 
0.6 mg SL at 11A.M. on day 7 
(placebo phase) 
 
0.4 mg IV at 11 A.M. on day 7 
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Administration of buprenorphine  
The volunteers spent the study days involving the dosing with buprenorphine in the 
study facility located in the Department of Pharmacology. The days started at 8 a.m. 
and the volunteers spent the next 23 hours in this facility.  
The volunteers fasted overnight (8 h) before the administration of buprenorphine. 
Standardized meals were served 4 and 8 h after buprenorphine administration. 
Volunteers were allowed to drink small amounts of water between the meals, but no 
other drinks were allowed. For nausea and vomiting, intravenous tropisetron was 
used, if needed. 
A single dose of 0.4 mg (0.6 mg during placebo phase) of sublingual 
buprenorphine (Temgesic 0.2 mg and 0.4 mg tablets; RB Pharmaceuticals Limited, 
Slough, Great Britain) was administered on the 5th day of pre-treatment in Study I.  
In Study II all subjects ingested a single dose of 0.2 mg (3.6 mg during placebo 
phase) of oral buprenorphine (Temgesic®0.2 tablet RB Pharmaceuticals Limited, 
Slough, Great Britain) at 11.00 on an empty stomach. Buprenorphine was packed in 
soluble capsules at the pharmacy to prevent absorption from mucous membranes. In 
Study III, the   subjects were given on the 7th day of pre-treatment sublingually 0.6 
mg or 0.8 mg buprenorphine (Temgesic 0.2 mg® resoriblets; RB Pharmaceuticals 
Limited, Slough, Great Britain) after placebo or rifampicin, respectively. In the 
second part of the Study III, subjects received an intravenous bolus of 0.4 mg 
buprenorphine (Temgesic 0,3 mg/ml® inj; RB Pharmaceuticals Limited, Slough, 
Great Britain) after rifampicin or placebo. The dosing schedule of buprenorphine is 
illustrated in Table 3. 
Pharmacokinetic and pharmacodynamic assessments 
Blood samples (10 ml) were collected into ethylenediaminetetraacetic acid 
containing tubes immediately before and 30 min, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18 h 
after the administration of buprenorphine for pharmacokinetic measurements. 
Plasma was separated within 30 min and stored at -70 °C until analysis. Urine was 
collected up to 18 hr after buprenorphine administration. Urine aliquots were stored 
at -70 °C until analysis. In Study III, another venous cannula was inserted into the 
opposite forearm to allow intravenous administration of buprenorphine. 
Adverse effects were evaluated using a questionnaire before, and 3 and 6 hours 
after buprenorphine administration. The subjective effects of buprenorphine were 
evaluated using a 100-mm visual analogue scale. The Maddox wing test (MWT) was 
used to measure the central coordination of extraocular muscles (Hannington-Kiff 
1970) and pupil size was measured with Cogan’s pupillometer (Cogan 1941). A digit 
symbol substitution test was used to estimate central processing of sensory 
information by recording the number of correct symbols substituted in 3 min (Stone 
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1984). The analgesic effect was evaluated using the cold pressor test. 
Pharmacodynamic reactions were evaluated prior to and at 1, 2, 3, 4, 5, 6, 8, 10 and 
12 h after buprenorphine administration.  
4.1.3 Determination of plasma drug concentrations 
Determination of buprenorphine and norbuprenorphine 
The plasma drug concentrations were analysed in the Department of Clinical 
Pharmacology, at the University of Helsinki, Helsinki, Finland. Mass spectrometric 
detection of buprenorphine and norbuprenorphine was carried out using an API 3000 
Triple Quadrupol tandem mass spectrometer (Applied Biosystems MDS Sciex, 
Toronto, ON, Canada) as previously described (Ceccato et al. 2003) with minor 
modifications. The internal standards (buprenorphine-D4 and norbuprenorphine-D3) 
were added to samples, quality control samples and reference standards before the 
subsequent pre-analytical procedures.  
Plasma and urine samples (0.5 ml) were prepared by use of a Bond Elut C8 solid 
phase extraction (Agilent Technologies, Lake Forest, CA, USA). Gradient 
chromatography was carried out using a Model 1100 Series liquid chromatograph 
(Agilent Tehcnologies) equipped with a binary pump, a vacuum degasser, a 
thermostatted column compartment and an autosampler. Atlantis HILIC Silica 
analytical column (2.1x100 mm; Waters, Milford, MA) with precolumn (2.1 mmx10 
mm; Waters) were used at 30 oC. The mobile phase A consisted of a mixture of 
acetonitrile: methanol: 10 mM ammonium formate + 0.2% formic acid (90:5:5, 
v/v/v), and the mobile phase B of 10 mM ammonium formate + 0.2% formic acid. 
The gradients were: 0-0.5 min B=0%, 0.5-5 min B→40%, 5-8 min B=40%, 8.0-8.1 
min B→0%, 8.1-20 min B=0%. The flow rate was 0.2 ml/min. The mass 
spectrometer was operated in the positive multi-reaction monitoring (MRM+) 
detection mode with electro-spray ionization. The selected ion transitions used for 
quantification were: m/z 468.3 to m/z 55.1 for buprenorphine, m/z 414.3 to m/z 
340.2 for norbuprenorphine, and m/z 472.3 to m/z 59.2 and m/z 417.3 to m/z 83.2 
for the internal standards, respectively.  
The lower limit of quantification (LLQ) for plasma buprenorphine was 0.02 
ng/ml, and for norbuprenorphine 0.05 ng/ml. For urine buprenorphine and 
norbuprenorphine the LLQ was 0.5 ng/ml. The inter-day coefficients of variation 
(CV%) were for plasma buprenorphine 8.0% at 5.3 ng/ml, 8.7 % at 0.5 ng/ml and 
6.1% at 0.05 ng/ml, and for norbuprenorphine 3.7% at 4.8 ng/ml, 8.7% at 0.48 ng/ml, 
and 11.9%% at 0.048 ng/ml. 
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Voriconazole and posaconazole 
Plasma concentrations of voriconazole and posaconazole in the samples taken on 
day 5 before the administration of buprenorphine were determined by a liquid 
chromatograph equipped with a Waters Symmetry C8 column (Waters) and UV-
detection at 255 nm as described before (Chhun et al. 2007). Diazepam was used as 
the internal standard, the limit of voriconazole and posaconazole quantification was 
10 ng/ml. The CVs for voriconazole and posaconazole were below 10% at relevant 
plasma concentration range, i.e. for voriconazole 7.5% at 4000 ng/ml, 3.0% at 1100 
ng/ml, and 5.5% at 110 ng/ml, and for posaconazole 5.0% at 4000 ng/ml, 1.7% at 
1100 ng/ml, and 9.4% at 110 ng/ml.  
4.1.4 Pharmacokinetic calculations 
The peak plasma concentrations (Cmax) and the corresponding time to Cmax (tmax) of 
buprenorphine and norbuprenorphine were observed directly from the data. The 
areas under the buprenorphine and norbuprenorphine plasma concentration–time 
curves (AUC) from 0 to 18 h (AUC0–18) were calculated by noncompartmental 
methods using WinNonlin pharmacokinetics program (version 4.1; Pharsight, 
Mountain View, CA). The terminal log-linear part of each concentration–time curve 
was identified visually, and the elimination rate constant (ke) was determined from 
the logarithmically transformed data using linear regression analysis. The t½ was 
calculated using the equation t½ = ln2/ke. The cumulative amount of unconjugated 
buprenorphine and unconjugated norbuprenorphine excreted into urine was 
calculated from 0 to 18 h (Ae), and the renal clearance (Clrenal) using the equation 
= Ae/AUC0-18. All pharmacokinetic parameters were normalized for a buprenorphine 
dose of 1.0 mg. 
4.1.5 Pharmacodynamic measurements 
Pharmacologic responses were evaluated prior to and at 1, 2, 3, 4, 5, 6, 8, 10 and 12 
h after buprenorphine administration. Adverse effects were evaluated using a 
questionnaire before, and 3 and 6 hours after buprenorphine administration. 
Subjective effects 
The subjective effects of buprenorphine were evaluated using 100-mm visual 
analogue scales for the following seven items: drowsy/alert, very poor 
performance/very good performance, no drug effect/very strong drug effect, 
relaxed/anxious, unpleasant feeling/pleasant feeling, no nausea/very strong nausea, 
calm/restless. The participants were asked if they were experiencing the following 
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adverse effects: dizziness, weakness, fever, headache, increased sweating, nausea, 
anxiety, sleeping disorders, dryness of the mouth, coordination disorder and 
tiredness.  
Maddox Wing Test 
The Maddox wing test was used to measure the central coordination of extraocular 
muscles (Hannington-Kiff 1970). The subject looked into the Maddox Wing 
apparatus and oblique and vertical wings divided their vision. In this test, the left eye 
sees a horizontal numbered scale and the right eye sees an arrow. Divergence of the 
eyes resulted in an image such as the arrow would move. The number at which the 
arrow seems to point when stopped is registered and this indicates the diopters.  
Cogan’s pupillometer 
 Pupil size was measured with Cogan’s pupillometer (Cogan 1941) as a measure of 
opioid effect. Subjects looked through black plastic sheet (Cogan’s pupillometer) 
with one eye in stable light conditions. In the sheet there was a column of small hole 
pairs at an increasing distance of 0.5 mm from each other. The volunteers found the 
first hole-pair where a separate view of each hole could be seen. The size of this 
hole-pair in millimetres represented the pupil size.  
Digit symbol substitution test 
A digit symbol substitution test was used to estimate central processing of sensory 
information by recording the number of correct symbols substituted in 3 min using 
pencil and paper (Stone 1984). A model of nine digits with corresponding symbols 
was presented at the top of the paper. A total of 300 digits (9 different) were 
organized in 12 rows on each paper in a randomized order. To prevent learning the 
order of the symbols was changed at every testing time point. Subjects had 3 minutes 
time to substitute digits with correct symbols and the number of correct symbols was 
recorded.  
Cold pain sensitivity 
The analgesic effect was evaluated using the cold pressor test. The subject immersed 
his/her hand up to the wrist in ice-cold water at a temperature of 0–2 °C. The time 
from the immersion to the first sensation of pain was defined as the cold pain 
threshold. Subjects reported the pain intensity and unpleasantness at 30 s and 60 s 
after immersion on a numerical rating scale (0 = no pain or unpleasantness, 100 = 
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maximal pain or unpleasantness). If pain became intolerable, the pain intensity was 
recorded as maximal (100).  
4.2 Clinical study 
4.2.1 Subjects 
Altogether 158 patients undergoing diagnostic or therapeutic colonoscopy in the 
Department of Endoscopies in the University Hospital of Turku were recruited to 
participate in this study. Male and female patients aged 18 to 80 years, with physical 
status (ASA) classified as I–III according to the American Society of 
Anesthesiologists’ guidelines, body mass index (BMI) < 35 and a weighing over 50 
kg scheduled for routine diagnostic or therapeutic colonoscopy were eligible for the 
study. Patients with previous gastrointestinal surgery, sleep apnea, chronic 
obstructive pulmonary disease, SpO2 <90%, pregnancy or nursing or concomitant 
drug therapy known to cause significant enzyme induction or inhibition of CYP 3A4 
were excluded. Further exclusion criteria were a history of intolerance to the study 
drug or related compounds, a history of alcoholism, drug abuse, psychiatric, 
psychological or other emotional problems that were likely to invalidate informed 
consent. Patient characteristics are summarized in Table 4. Subjects were informed 
about the study before the procedure and they were told that participating was fully 
optional and participating or refusal would not affect their treatment in any way. 
Table 4.  Patient demographic characteristics in Study IV. 
  Placebo Fentanyl 
Mean age, years (±SD)  59.9 ± 13,5 57.9 ± 13.6 
Male/female, n  39/33 39/33 
Mean height, cm (±SD)  170 ± 9.7 172 ± 8.9 
Mean weight, kg (±SD)  79.3 ± 14.8 82.9 ± 19.5 
Median length of the procedure, min 
(range)  15 (5-40) 20 (5-50) 
Median time between the end of 
colonoscopy and hospital checkout, min 
(range) 
 25 (5-90) 25 (9-60) 
4.2.2 Study design 
A randomized double-blind and placebo-controlled study design was used. Subjects 
were randomized to receive either sublingual Fentanyl (Abstral ® 100 µg, 
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ProStrakan) or a placebo ten minutes before the procedure. The patients were 
randomized into two groups by using the sealed envelope technique. All patients, 
investigators, and staff members involved in the conduct of the study were blinded 
to treatment assignment. Patients were instructed not to swallow the tablet but to 
allow it to dissolve completely in the sublingual cavity without chewing or sucking. 
Patients were not allowed to eat or drink anything until the sublingual tablet had 
completely dissolved. 
The patients assessed the average pain using a numerical rating scale (NRS 0-
10) during the procedure and at the end of colonoscopy. Adverse effects of opioids 
(nausea/drowsiness) and patients’ subjective effects were recorded at the end of 
colonoscopy. The patients also scored their overall satisfaction with the procedure 
prior to discharge. The adverse effects of opioids were evaluated using NRS (0-10) 
for the following items: drowsiness (alert / very drowsy), pleasantness (very 
unpleasant / very pleasant feeling), and nausea/vomiting (no nausea / very strong 
nausea). Furthermore, the endoscopist and the assisting nurse evaluated using NRS 
whether the patient seemed to experience pain, the level of sedation, nausea and 
judged the overall flow of the procedure at the end of colonoscopy. The endoscopist 
also estimated the level of technical difficulties associated with the colonoscopy. 
SpO2 and respiratory rate were followed throughout the procedure. If the 
peripheral arterial oxygen saturation decreased below 90 % or respiratory rate 
decreased below 8 per min, additional oxygen was given. In case of excessive opioid 
effects, 0.1 mg of naloxone was to be administered.    
The patients were interviewed by telephone on the first day after the procedure. 
The patients assessed their anxiety before the procedure by using a scale from 1 to 4 
(1= no anxiety, 4= maximal anxiety). Patients evaluated how well they could 
remember events during and after the colonoscopy on a scale from 1 to 4 
(1=remember everything, 4= cannot remember anything). The level of abdominal 
pain was assessed using a scale from 1 to 4 (1= no pain, 4=a lot of pain). Patients 
were also asked whether they had experienced any adverse effects during the day 
after the procedure such as abnormal tiredness, nausea or dizziness and evaluated 
these symptoms from 1 to 4 (1= no drowsiness/nausea/dizziness, 4= great amount of 
drowsiness/nausea/dizziness). Patients assessed the unpleasantness of the 
colonoscopy from 1 to 4 (1= not at all, 4= very unpleasant). 
4.3 Statistical analysis 
Based on previous studies (Hagelberg et al. 2009; Hynninen et al. 2007; Saari et al. 
2010) it was estimated that 10 subjects would be required to detect a 30% difference 
in the AUC0–∞ of buprenorphine at a power of 80% and a level of significance P < 
0.05. Enrolling 12 subjects allowed a 20% dropout rate.  
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The data from interaction studies were evaluated for the normality of distribution 
using probit plots and the Shapiro–Wilk’s W-test. Data were log-transformed for 
analysis but are reported as nontransformed results. The AUC0–∞ of buprenorphine 
was the primary outcome variable in Studies I and III and the AUC0-18 of 
buprenorphine in Study II. Geometric mean ratios with 90% CIs were calculated for 
the pharmacokinetic variables. A lack of interaction was assumed if the 90% CI of 
the geometric mean ratios for pharmacokinetic variables were within the acceptance 
limit of 0.8–1.25. Differences in pharmacokinetic variables between study drug and 
placebo phases were analysed using paired Student’s t-test except for tmax which was 
analysed using the Wilcoxon signed-ranks test. In Study II, the Pearson product 
moment correlation coefficient was used to investigate the possible relationship 
between the ratios of the AUC0–18 of buprenorphine during the treatment phase 
(voriconazole) to the AUC0–18 of buprenorphine during the control phase, as well as 
to the Ctrough of voriconazole before the administration of buprenorphine. Differences 
were regarded as statistically significant at p < 0.05. The results are expressed as 
mean values ± SD.  The possible association of plasma buprenorphine 
concentrations with psychomotor and analgesic effects were also calculated using 
the Pearson’s product moment correlation coefficient. The results are expressed as 
mean values ± SD. All data were analysed using SYSTAT for Windows (version 
10.2; Systat Software, Richmond, CA) in Studies I and III and R software (version 
3.2.0) and ggplot2 (version 2.1.0) was used for statistical analysis and graphical 
presentation in Studies II and III. 
A total of 150 patients was planned to be enrolled in Study IV. The sample size 
was determined based on results of previous studies (Pambianco et al. 2016; Amer-
Cuenca et al. 2011) with similar design and was expected to provide adequate data 
to examine the applicability of sublingual fentanyl during colonoscopy. The primary 
efficacy endpoint was the amount of pain as assessed with the NRS score. The 
primary efficacy analysis was summarized descriptively for overall success and 
within each category by treatment group. P values from chi-square tests (or Fisher 
exact tests as appropriate) or an analysis of variance model with treatment as the 
main overall effect with pairwise comparisons being conducted for descriptive 
purposes. 
4.4 Ethical considerations 
All study protocols were approved by the Ethics Committee of the Hospital District 
of Southwest Finland and by the Finnish National Agency for Medicines. The trials 
were registered before patient enrolment at clinicaltrials.gov and in the EudraCT 
database. Verbal and written information was delivered to volunteers in Studies I-III 
before they decided to participate in the study. They gave written informed consent 
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before starting the study. A written informed consent was obtained from each patient 
in Study IV. Volunteers and patients were told that they could withdraw from the 
study at any time. The dosages of the drugs were considered safe and the studies 
were conducted in facilities where any serious adverse effect could be treated 
appropriately.  
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5 Results 
5.1 Interaction studies 
5.1.1 Pharmacokinetic results 
Mean changes in the pharmacokinetic parameters of buprenorphine and 
norbuprenorphine during the treatment periods are shown in Figures 3 and 4. The 
effects of pre-treatments on the pharmacokinetics of buprenorphine are summarized 
in Table 5. 
Effect of voriconazole on sublingually administered buprenorphine 
Voriconazole elevated the plasma concentrations of sublingually administered 
buprenorphine significantly. Compared to the placebo phase, the mean AUC0-∞ of 
sublingually administered buprenorphine was increased by voriconazole by 1.80-
fold (GMR 1.80; 90% CI of GMR: 1.45, 2.24; p<0.001). The presence of 
voriconazole increased the Cmax of sublingually administered buprenorphine by 1.37-
fold (GMR 1.37; 90% CI of GMR: 1.05, 1.79; p<0.001) and the mean t½ from 7.9 h 
to 11.0 h (p<0.001). During all three study phases, in Study I, when buprenorphine 
was administered sublingually, the plasma concentrations of norbuprenorphine were 
around or below the LLQ in the most plasma samples.  
Effect of voriconazole on orally administered buprenorphine 
When buprenorphine was administered orally, voriconazole was found to increase 
the plasma concentrations of buprenorphine and norbuprenorphine significantly. The 
mean AUC0-18 of oral buprenorphine was increased by voriconazole by 4.3-fold 
(90% CI 2.7, 6.7 p<0.001). Voriconazole increased the Cmax of oral buprenorphine 
3.9-fold (90% CI 2.6, 5.9; p<0.001). Voriconazole slightly prolonged the t½ of oral 
buprenorphine (P < 0.05) but had no significant effect on the tmax of orally 
administered buprenorphine. When buprenorphine was administered orally, 
voriconazole increased the mean AUC0-18 of norbuprenorphine nearly 4-fold (90% 
CI 3.0, 5.3; p<0.001), and its Cmax 3.3-fold (90% CI 2.4, 4.4; p<0.001). 
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Effect of posaconazole on sublingually administered buprenorphine 
Posaconazole increased the exposure to sublingual buprenorphine, but the effect was 
rather small. Compared to the placebo phase, the mean AUC0-∞ of sublingually 
administered buprenorphine was increased by the presence of posaconazole by 1.25-
fold (90% CI 1.03-1.52; p=0.016). Posaconazole increased the Cmax of sublingual 
buprenorphine by 1.20-fold (0.97-1.48) but the effect was not statistically significant 
(p=0.206). Posaconazole had no effect on the t½ of sublingual buprenorphine. 
Posaconazole tended to decrease the excretion of norbuprenorphine into urine. 
Effect of rifampicin on sublingually administered buprenorphine  
Rifampicin reduced the exposure to sublingual buprenorphine. When compared to 
placebo, the mean AUC0–18 of sublingual buprenorphine was decreased by rifampicin 
by 25% (GMR: 0.75; 90% CI of GMR: 0.60, 0.93). The bioavailability of 
sublingually delivered buprenorphine decreased by rifampicin from the control value 
of 22 to 16%, but the influence was not statistically significant (GMR: 0.84; 90% CI 
of GMR: 0.62, 1.13).  
Effect of rifampicin on intravenously administered buprenorphine  
Compared to placebo, the presence of rifampicin did not exert any statistically 
significant effect on the plasma buprenorphine concentrations after intravenous 
buprenorphine administration.  
Effects on the renal excretion of buprenorphine and norbuprenorphine 
Voriconazole increased the cumulative amount of norbuprenorphine excreted in 
urine by 1.6-fold (90% CI 1.18-2.12; p<0.001), when buprenorphine was 
administered sublingually. In no study phase, in Study I, could the concentrations of 
parent buprenorphine in urine be reliably quantified as they were much lower than 
those of norbuprenorphine. Voriconazole increased the amount of unconjugated 
buprenorphine excreted in urine (p<0.001) but had no significant effect on its Clrenal 
when buprenorphine was administered orally, because also the AUC0–18 of 
norbuprenorphine was increased. The Ae of unchanged unconjugated buprenorphine 
was less than 0.1% of the dose during 18 hours even during the voriconazole phase. 
When buprenorphine was administered orally, voriconazole enhanced the Ae of 
unconjugated norbuprenorphine by 1.5-fold only (p<0.02) and voriconazole 
significantly (P < 0.001) reduced its Clrenal. 
The cumulative excretion of free, nonconjugated norbuprenorphine in urine was 
decreased by rifampicin by 65% after sublingual (GMR: 0.35; 90% CI of GMR: 
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0.24, 0.51) and by 52% after intravenous administration of buprenorphine (GMR: 
0.48; 90% CI of GMR: 0.39, 0.58), but the effect on buprenorphine excretion was 
less consistent. 
The mean Ctrough of voriconazole on day 5 was 1522 ng/ml and the mean Ctrough 
of posaconazole on day 5 was 967 ng/ml in Study I. The mean plasma concentration 
of voriconazole (Ctrough) was 1022 ng/ml in Study II.  
 
 
Figure 3.  The mean AUC(0-18) and Cmax of buprenorphine after pre-treatment with oral voriconazole 
(vori), posaconazole (posa) or rifampicin (rifa) expressed as geometric mean ratios with 
the 90% confidence interval. Values are normalized for a buprenorphine dose of 1.0 mg. 
Bupre = Buprenorphine, po = per oral, sl = sublingual, iv =intravenous.  
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Figure 4.  The mean amount of norbuprenorphine excreted into urine (Ae) within 18 h after pre-
treatment with oral voriconazole (vori), posaconazole (posa) or rifampicin (rifa) 
expressed as geometric mean ratios with the 90% confidence interval. Values are 
normalized for a buprenorphine dose of 1.0 mg. Bupre = Buprenorphine, po = per oral, 
sl = sublingual, iv =intravenous. 
Table 5.  Pharmacokinetic parameters of buprenorphine after sublingual (sl), oral (po) or intravenous (iv) buprenorphine administration on the fifth day 
of pre-treatment with oral placebo (plac), voriconazole (vori), posaconazole (posa) or on the seventh day of pre-treatment with oral placebo 
or rifampicin (rifa). Values are normalized for a buprenorphine dose of 1.0 mg. Data are shown as mean ± standard deviation (SD), and as P 
values in parenthesis compared to placebo - except for the tmax, which  is given as median and range. 
Study  Cmax (ng/ml) tmax (h) AUC(0-18) (ng. h/ml) t½(h) Ae (µg) 
I Plac (sl Bupre) 
Vori (sl Bupre) 
Posa (sl Bupre) 
0.70±0.20 
0.96±0.27 (0.013) 
0.84±0.27 (0.159) 
2.0 (1.0-3.0) 
2.0 (1.5-3.0) (0.40) 
2.0 (1.5-3.0) (0.667) 
4.1±1.2 
6.5±1.7 (<0.001) 
5.0±1.3 (0.026)  
7.9±2.8 
11.0±3.9 (<0.001) 
8.1±2.9 (0.991) 
5.7±2.2 
9.0±3.1 (<0.001) 
4.8±2.2 (0.239) 
II Plac (po Bupre) 
Vori (po Bupre) 
0.057±0.031 
0.22±0.23 (<0.001) 
0.5 (0.5-18) 
2 (0.5-10) (0.06) 
0.43±0.26 
2.1±1.4 (<0.001) 
9.1±2.4 
14.5±6.8 (0.042) 
0.10±0.063 
0.53±0.29 (<0.001) 
III Plac (sl Bupre) 
Rifa (sl Bupre) 
Plac (iv Bupre) 
Rifa (iv Bupre) 
0.36±0.15 
0.30±0.17 (0.041) 
- 
- 
1.5 (1-3) 
2 (1-3) 
1.64±0.74 
1.36±0.87 (0.035) 
5.32±3.18 
4.53±1.64 (0.37) 
- 
- 
- 
- 
4.35±1.85 
1.47±0.66 (<0.001) 
4.6±1.9 
2.3±1.1 (<0.001) 
Cmax, peak plasma concentration; tmax, concentration peak time; AUC(0-18), area under curve from 0 to 18 h; t½, elimination half-life; Ae, amount of 
norbuprenorphine excreted into urine within 18 h.
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5.1.2 Pharmacodynamic results 
Between the study phases, there were no statistically significant differences in the 
pharmacological effects of buprenorphine. There was a linear correlation between 
the plasma buprenorphine concentration and the pharmacological drug effect. Due 
to different buprenorphine doses, it was not possible to make a relevant comparison 
of pharmacological effects caused by sublingual and oral buprenorphine.   
Adverse effects 
Most of the subjects experienced some mild and moderate adverse effects, but there 
were no severe adverse effects. Mild dizziness, sedation and nausea were the most 
common adverse effects. During Studies I and II, there were no adverse effects 
encountered that would have required treatment.  
In study III, adverse effects were more frequent, especially when buprenorphine 
was administered intravenously. All subjects experienced mild-to-moderate adverse 
effects. Some of the subjects needed medication (tropisetron) to treat the nausea 
occurring after buprenorphine. Intravenous administration of buprenorphine caused 
more nausea than its sublingual counterpart. During the intravenous part of the study, 
itching and urticaria also were encountered and eight subjects needed medication 
(cetirizine hydrochloride) for these symptoms. 
5.2 Clinical study 
The patient, endoscopist and assisting nurse assessed subjective parameters (pain, 
sedation, nausea, dizziness, co-operation, unpleasantness) by using a numerical 
rating scale (0-10). The patients assessed subjective parameters (nausea, dizziness, 
stomach pain, unpleasantness) by using a numerical rating scale (0-4) in a post-
procedure interview by telephone interview on the first day after the procedure. 
5.2.1 Pain and sedation scores 
There was no difference between the placebo and intervention groups in the level of 
pain and sedation. Patients assessed their average and maximum pain during 
colonoscopy. The median pain [IQR] experienced by the patients was 4.5 [2-7] in 
the intervention group and 5 [3-6.5] in the placebo group. The median values for 
pain were 5 in female and 4 in male patients but there was no statistically significant 
difference between male and female patients. The maximum pain patients 
experienced was 8 [5-9] in the placebo group and 7 [4.8-8] in intervention group. 
The endoscopist and assisting nurse also assessed the average pain of the patients. 
The endoscopist assessed median pain to be 5 [2-7] in the placebo group and 5.5 in 
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[3-8] in the fentanyl group. The corresponding values estimated by the assisting 
nurse were 6 [2-7] and 6 [3-8], respectively.  
The median self-assessed level of sedation using the NRS was 0 [0-0] in both 
groups. The endoscopist assessed the sedation level to be 0 [0-1] in both groups.  The 
assisting nurse assessed the sedation level to be 0 [0-1] in the placebo group and 1 
[0-2] in the fentanyl group.  
5.2.2 Adverse effects  
No desaturation events were recorded in either of the groups. Respiratory rates were 
above 8 per minute and naloxone was not needed in any of the patients. There was 
no nausea in either group. Patients assessed nausea on the numerical rating scale 
from 0 to 10 and the median was 0 [0-0] in the placebo group and 0 [0-1] in the 
intervention group. Furthermore, according to endoscopist’s or assisting nurse’s 
assessment, the patients did not suffer from nausea.  
The post-procedural interview during the following day after colonoscopy 
showed no differences in patient experiences between the intervention and placebo 
groups. The patients assessed their nausea to be 1 [1-1] in both groups.  
5.2.3 Success of the procedure and recovery after 
colonoscopy 
Three procedures had to be interrupted in both groups. Excessive pain interrupted 
the procedure in one patient in the intervention group and in two patients in the 
placebo group. The median length of the procedure was 15 (range 5-40) minutes in 
the placebo group and 20 (range 5-50) minutes in the fentanyl group, respectively. 
There were no significant differences between the two groups in the times between 
the end of colonoscopy and hospital discharge. The median time between these two 
events was 25 (range 9-60) minutes in the intervention and 25 (range 5-90) minutes 
in the placebo group. Patients were asked to assess the post-procedural stomach pain 
on a scale of 1-4 on the following day after the colonoscopy. The median stomach 
pain was 1 [1-2] in both groups. They were also asked how well they remembered 
the previous day's events and there was no difference between the groups. 
The assessment of subjective parameters by patient, endoscopist and nurse using 
the numerical rating scale (0-10) are summarized in Table 6.  
 
 
Table 6.  Assessment of subjective parameters by patient, endoscopist and nurse using the numerical rating scale (0-10). Data are shown as median and 
interquartile range.  
Parameter Patient  Endoscopist  Nurse Fentanyl Placebo p-value  Fentanyl Placebo p-value  Fentanyl Placebo p-value 
Progression of 
procedure NA NA -  9 [8-10] 9 [8-10] 0.992  8 [7-9] 9 [7-9] 0.834 
Co-operation NA NA -  10 [9.75-10] 10 [9.75-10] 0.132  10 [9-10] 10 [9-10] 0.752 
Average pain 4.5 [2-7] 5 [3-6.5] 0.852  5 [2-7] 5.5 [3-8] 0.132  6 [2-7] 6 [3-8] 0.716 
Maximum pain 7 [4.75-8] 8 [5-9] 0.212  NA NA -  NA NA - 
Sedation NA NA -  0 [0-1] 0 [0-1] 0.910  1 [0-2] 0 [0-1] 0.093 
Nausea 0 [0-1] 0 [0-0] 0.255  0 [0-0] 0 [0-0] 0.568  0 [0-0] 0 [0-0] 0.603 
Unpleasantness 4 [2-6] 5 [3-7] 0.369  NA NA -  NA NA - 
Drowsiness 0 [0-0] 0 [0-0] 0.595  NA NA -  NA NA - 
NA = Not applicable
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6 Discussion 
6.1 Interaction studies 
6.1.1 Methodological considerations 
The three interaction studies were conducted using a single-blinded, randomized, 
balanced cross-over study design. On the basis of previous drug-drug interaction 
studies (Nieminen et al. 2009; Saari et al. 2006), it was calculated that 10 subjects 
would be needed to detect a 30 % difference in the area under the concentration-time 
curve (AUC0-∞) of buprenorphine at a power of 80% and a level of significance of 
P<0.05. To allow for possible dropouts, 12 healthy non-smoking volunteers were 
recruited to each of the three studies. Each of the volunteers served as their own 
control which minimized the effect of inter-individual variability and the number of 
volunteers could be kept relatively low. This was an academic study and we had no 
possibility to use identical placebo tablets, especially when posaconazole is 
administered as a mixture. It was impossible to use a double-blinded study design 
and even though volunteers were not told which drug they received it is theoretically 
possible that they would guess the pre-treatment used. Our primary aim was to study 
the pharmacokinetics of buprenorphine. Nonetheless, it was unlikely that the method 
of blinding would affect the outcome.  
We had a four weeks’ interval between the study phases. This was considered 
sufficient to eliminate any possible carry-over effects. The same wash-out period 
was chosen in all of the three studies to minimize the possible effects of menstrual 
cycle on the results of female volunteers although studies have found no significant 
differences in the pharmacokinetics of CYP3A4 substrates during different 
hormonal stages (Kharasch et al. 1997).  
Before administering the substrate drug, it would be preferable to reach the 
steady state of the inhibitor or inducer in use. Therefore, we provided a loading dose 
when voriconazole was administered and according to the literature, steady-state 
should be achieved on day two although there is wide variability between individuals 
in terms of concentrations (Purkins et al. 2003). With posaconazole, it takes 10 days 
to reach steady-state concentrations with oral twice-daily dosing (Courtney et al. 
2003). The posaconazole pre-treatment was only for 5 days, because it would have 
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been unethical to expose healthy volunteers to such a long antifungal treatment. 
However, interactions with posaconazole have also been described after short dosing 
period (Krishna et al. 2012).  
With rifampicin, a true steady-state was not achieved due to its autoinduction, 
which occurs over 2 weeks.  The repeated administration of rifampicin reduces its 
oral bioavailability and increases its clearance (Loos and Musch 1985).  
The compliance was assured for voriconazole and posaconazole with 
determination of their concentrations from plasma samples taken before 
administration of buprenorphine. In Study III, it was not possible to determine the 
rifampicin concentration in blood but in all of the three studies, compliance with pre-
treatment was also controlled with SMS technology. If the message was delayed, the 
subject was reminded to take the pre-medication.  
The dose of buprenorphine was low, because all the volunteers were opioid naïve 
and we wanted to ensure their safety. In Study I and in the first two phases of study 
III, buprenorhine was administered sublingually. Volunteers were instructed to let 
the tablet dissolve completely under the tongue, but we cannot rule out the possibility 
that part of the drug was swallowed. In Study II, buprenorphine was administered 
orally and there were extensive differences between the buprenorphine doses in the 
placebo and intervention phases. We assumed low oral bioavailability and chose a 
higher buprenorphine dose in the placebo phase. In the voriconazole phase, we 
wanted to keep the dose small because of the possibility of strong inhibition of the 
metabolism of buprenorphine.  
The pharmacodynamic effects of buprenorphine were evaluated with methods 
used in earlier interaction studies with opioids (Saari et al. 2010; Saarikoski et al. 
2013; Nieminen et al. 2010). We used VAS-scores, Maddox Wing Test, Cogan’s 
pupillometer, digit symbol substitution test, cold pressor test and recorded adverse 
effects in every study. We used the cold pressure test, because it is known to be a 
sensitive model for  opioid induced analgesia in healthy volunteers (Posner et al.  
1985) and it is also straightforward to conduct. There was a linear correlation 
between the plasma buprenorphine concentration and the pharmacological effect in 
all pharmacodynamic variables, but their relevant comparison between the study 
phases was not possible due to the different buprenorphine doses in these different 
trials. 
Almost every subject experienced some mild or moderate adverse effects. The 
most common adverse effects were mild dizziness and nausea. Especially in Study 
III where buprenorphine was administered intravenously, the volunteers relatively 
frequently experienced adverse effects. In Study III, tropisetron was used to treat 
nausea which theoretically might have affected the results. However, its effect on 
our results was most likely minimal because tropisetron is a substrate and not an 
inhibitor of CYP2D6 (Ho and Gan 2006). Itchiness and urticaria were treated with 
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cetirizine a drug which has a negligible interaction with liver enzymes (Cheng 2008), 
and therefore the provision  of cetirizine most likely did not influence the results of 
the present study.   
6.1.2 Pharmacokinetic considerations 
Effect of CYP3A4 inhibition 
Voriconazole, a strong CYP3A4 inhibitor, affected significantly the 
pharmacokinetics of sublingually and orally administered buprenorphine. In 
contrast, the effect of posaconazole on the exposure of sublingually administered 
buprenorphine was not significant. 
Compared to placebo, voriconazole increased the mean AUC0-∞ of sublingual 
buprenorphine by 1.80-fold and its Cmax by 1.37-fold. Voriconazole increased the 
mean AUC0-18 of oral buprenorphine 4.3-fold and its Cmax 3.9-fold compared to 
placebo. Compared to placebo, posaconazole increased the mean AUC0-∞ of 
sublingual buprenorphine by 1.25-fold and its Cmax by 1.20-fold. In previous studies 
examining drug-drug interactions between HIV protease inhibitors and high-dose 
sublingual buprenorphine, ritonavir increased the AUC of buprenorphine 
significantly (57%) (McCance-Katz et al. 2006). Atanavir alone increased the 
buprenorphine AUC value by 93%; when atanavir was given together with ritonavir 
buprenorphine’s AUC was elevated by 67%, and the sedative effect of 
buprenorphine was also significantly increased. These interactions with 
buprenorphine are of the same order as those observed in the present study.  
There are several previous studies where voriconazole and posaconazole have 
been found to inhibit the metabolism of CYP3A4 substrates. Voriconazole has been 
found to increase the peak concentration and AUC values of oral midazolam by 3.8- 
and 10.3-fold, respectively (Saari et al. 2006). It has been shown that posaconazole 
at a daily dose of 400 mg increased the AUC of oral midazolam by 6.2-fold and Cmax 
by 2.4-fold (Krishna et al. 2009). Voriconazole increased also the peak concentration 
of oral oxycodone by 1.7-fold and its AUC by 3.6-fold (Hagelberg et al. 2009). The 
presence of voriconazole increased the exposure to sublingual buprenorphine 
significantly less than it has been reported to alter that of orally delivered midazolam. 
Sublingual buprenorphine seems to be less susceptible to the effects of drugs 
affecting intestinal and hepatic CYP3A4 during the first-pass; this is probably due 
to its partial bypassing of the intestinal first-pass metabolism.  
The urinary excretion of norbuprenorphine was also measured. This metabolite 
can be excreted into urine to some extent also in the unconjugated form because it is 
less lipophilic than the parent compound, buprenorphine. Surprisingly, the amount 
of norbuprenorphine excreted into urine during 18 hours after sublingual 
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buprenorphine dosing was increased by voriconazole by 58%. It would be expected 
that voriconazole would decrease the CYP3A4-mediated N-dealkylation of 
buprenorphine to norbuprenorphine because voriconazole is a strong inhibitor of 
CYP3A4. On the other hand, posaconazole is also a strong and selective CYP3A4 
inhibitor but posaconazole actually decreased the excretion of norbuprenorphine into 
urine, consistent with inhibition of its CYP3A4-mediated formation. Inhibition of 
CYP3A4-mediated N-demethylation and the strong inhibition of CYP2C9 and 
CYP2C19 mediated alternative pathways by voriconazole may partially explain why 
voriconazole increased the urinary excretion of norbuprenorphine and increased 
buprenorphine concentrations much more than posaconazole. Norbuprenorphine is 
known to be a substrate of P-gp (Tournier et al. 2010). Posaconazole is a potent 
inhibitor of P-gp, while voriconazole is a weak inhibitor of this transporter. This may 
partially explain the smaller effect of posaconazole on the buprenorphine plasma 
concentrations and urinary excretion of norbuprenorphine compared to 
voriconazole. In addition, the increased urinary excretion of the metabolite may 
involve unidentified membrane transporter mechanisms. When buprenorphine was 
administered orally, voriconazole increased the amount of unconjugated 
buprenorphine excreted in urine (p<0.001). Voriconazole had no significant effect 
on Clrenal of buprenorphine but it reduced the Clrenal of norbuprenorphine.  
Norbuprenorphine, but not buprenorphine, is a substrate of the efflux transporter P-
gp, so the reduction of Clrenal can be explained by the inhibition of membrane 
transporters.  
The effects of voriconazole on parent buprenorphine can be mainly explained by 
inhibition of CYP3A4 during the first pass and elimination phases. Inhibition of 
CYP3A4 should decrease the N-dealkylation of buprenorphine to norbuprenorphine. 
However, the substantial increases in the AUC and Cmax of norbuprenorphine 
suggest the presence of additional mechanisms. Buprenorphine and 
norbuprenorphine are also glucuronidated by UGTs.  Buprenorphine is mainly 
glucuronidated by UGT2B7, while norbuprenorphine glucuronidation is 
predominantly mediated by UGT1A3 (Rouguieg et al. 2010) The effects of 
posaconazole, voriconazole and their metabolites on the different UGTs and 
glucuronidases are not known. However, voriconazole has been claimed to act as an 
UGT2B inhibitor in the gut and liver, according to a semi-physiological population 
pharmacokinetic model (Frechen et al. 2013).  
These results seem to emphasize the significant role of CYP3A-mediated first-
pass metabolism of buprenorphine, which is only partially bypassed by sublingual 
administration. The bioavailability of orally administered buprenorphine is low (~15 
%), but sublingual administration increases the drug’s bioavailability up to 30-60% 
(Mendelson et al. 1997; Nath et al. 1999). Both the Cmax and AUC of buprenorphine 
were clearly increased after voriconazole and the present results clearly suggest that 
Mari Fihlman 
 56
concomitant treatment with strong CYP-inhibitors may increase the bioavailability 
of sublingual buprenorphine. Most probably, voriconazole caused increased 
exposure by inhibiting both the intestinal and hepatic CYP3A enzymes, increasing 
both the Cmax and t½ of buprenorphine. In addition, other mechanisms such as 
inhibition of P-gp and UGTs may also be involved. 
Effect of CYP3A4 induction 
Rifampicin decreased the mean AUC0-18 of sublingual buprenorphine by 25%. The 
bioavailability of sublingual buprenorphine tended to decrease from 22% to 16% 
with rifampicin, but the change was not statistically significant. Rifampicin did not 
exert a statistically significant effect on the concentrations of intravenously 
administered buprenorphine. Rifampicin decreased the cumulative excretion of free, 
non-conjugated norbuprenorphine in urine by 65% after sublingual, and by 52% after 
intravenous administration, but the effect on buprenorphine excretion was less 
consistent. The induction of CYP3A4 activity by rifampicin in the intestinal wall and 
liver is the most likely the explanation for this finding, but enhancement of UGT or 
P-gp activities may also be play a role. A previous study has shown that rifampicin 
600 mg administered daily for 15 days decreased the mean AUC of high-dose 
buprenorphine by 70% and withdrawal symptoms were frequent.  (McCance-Katz et 
al. 2011). In this present study, the effect of rifampicin on the exposure to 
sublingually administered buprenorphine was smaller. The large difference between 
buprenorphine doses in these two trials and the shorter duration of rifampicin 
treatment may explain these discrepant findings.  
 Sublingually administered buprenorphine only partially avoids the induction of 
CYP3A4-mediated gastrointestinal metabolism by rifampicin. Hence, the sublingual 
route of administration of buprenorphine is more vulnerable to the effects of an 
interaction with rifampicin than the intravenous counterpart. Rifampicin has been 
found to decrease exposure to many other substrates of CYP3A4. Rifampicin 
decreased the AUC of oral and intravenous oxycodone by 86% and 53%, 
respectively,(Nieminen et al. 2009) and it  has been found to decrease the AUC of 
oral tramadol by 59% and intravenous tramadol by 43% (Saarikoski et al. 2013). 
Rifampicin  was also reported to enhance the activities of UGTs and P-gp  (Greiner 
et al. 1999; Niemi et al. 2003; Soars et al. 2004). Buprenorphine and 
norbuprenorphine are conjugated to B3G and N3G by UGTs and it is possible that 
the pharmacokinetic changes seen in this study are due to the enhanced activity of 
UGTs evoked by rifampicin (Chang Y 2009). The role of the P-gp in the transport 
of buprenorphine in humans is less clear although in vitro studies in rodents suggest 
that norbuprenorphine, but not buprenorphine is a substrate for P-gp (Hassan et al. 
2009; Brown et al. 2012). 
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The amount of unconjugated norbuprenorphine in urine was decreased by 
rifampicin when the participants were administered both sublingual and intravenous 
buprenorphine. This may be due to a shift in the metabolic pathway towards 
hydroxylation of buprenorphine or norbuprenorphine by CYP3A4. The induction of 
further metabolism of norbuprenorphine by UGTs after rifampicin pretreatment is 
also possible (Chang, Moody, and McCance-Katz 2006; Chang and Moody 2009).   
6.1.3 Pharmacodynamic considerations 
These studies were designed to explore the pharmacokinetics of buprenorphine. 
However, we also wanted to collect pharmacodynamic data to evaluate the 
pharmacological effect of buprenorphine in healthy volunteers. There was a linear 
correlation between the plasma buprenorphine concentration and the 
pharmacological effect in all pharmacodynamic variables, but their relevant 
comparison between the study phases was not possible due to the different 
buprenorphine doses given in the trials. When buprenorphine was administered 
sublingually or orally almost every subject experienced some mild or moderate 
adverse effects. The most frequent adverse effect was sedation, followed by ataxia, 
dizziness and nausea but in Studies I and II and the first two phases of Study III, 
these adverse effects were transient and did not require any treatment. When 
buprenorphine was administered intravenously, adverse effects were more frequent 
and more intense and several patients needed medication to relieve nausea or itching.  
6.1.4 Limitations of the study 
There are limitations in these studies; we normalized the pharmacokinetic values to 
a buprenorphine dose of 1 mg, because these studies were designed mainly to 
evaluate the pharmacokinetics of buprenorphine and its susceptibility to DDIs. 
However, dose normalization cannot be used for assessing pharmacodynamical 
results and subjective adverse effects. If buprenorphine had nonlinear 
pharmacokinetics, the use of different doses of buprenorphine during various phases 
of the study might have biased the dose-corrected results. In humans, there is no 
indication for nonlinear buprenorphine pharmacokinetics over a wide dosage range 
from 0.06 to 12 mg (Huestis et al. 2013; Bai, Xiang, and Finn 2016; McAleer et al. 
2003), although the pharmacokinetics of buprenorphine has been reported to be 
nonlinear in rats (Gopal, Tzeng, and Cowan 2002). We took blood samples for 18 
hours and a longer sampling time could have increased the reliability in the 
pharmacokinetic calculation, especially in determining the elimination half-life. 
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6.1.5 Clinical aspects 
These present results show that the interaction between voriconazole and sublingual 
buprenorphine may have a considerable clinical relevance in individual patients. 
Exposure to sublingual buprenorphine increases significantly even during a short 
treatment with clinically used doses of voriconazole. The exposure to buprenorphine 
may increase by more than 100% in some individuals receiving voriconazole. When 
triazole antifungals, especially voriconazole, are used with sublingual 
buprenorphine, careful patient monitoring is recommended. It is less likely that 
posaconazole would evoke a clinically significant interaction with sublingual 
buprenorphine. Patients receiving high-dose buprenorphine maintenance therapy 
often miss-use other opioids and benzodiazepines intravenously. This exposes them 
to various infections including fungal infections. If voriconazole is used to treat 
fungal infection with a patient receiving high-dose sublingual buprenorphine 
therapy, the dose of buprenorphine might even need to be reduced to the half of the 
normal dose.  
In clinical use, buprenorphine is not administered orally, but part of the 
sublingually administered drug can be swallowed. This study shows that 
voriconazole increases the bioavailability of oral buprenorphine significantly and 
concomitant use of voriconazole and sublingual buprenorphine may result in a 
clinically relevant interaction.   
In study III, rifampicin decreased the bioavailability and exposure to a low dose 
of sublingual buprenorphine but did not affect the exposure to intravenous 
buprenorphine. This interaction may diminish the effects of sublingual 
buprenorphine. A previous study revealed that when opioid-dependent subjects on 
stable doses of sublingual buprenorphine/naloxone were treated with oral rifampicin 
for 15 days, a 70% decrease in the mean AUC of buprenorphine was detected, and 
withdrawal symptoms were frequent (McCance-Katz et al. 2011). This present study 
showed that rifampicin has no effect on the concentrations of buprenorphine when 
the latter drug was administered intravenously. This finding is clinically important, 
because sublingual buprenorphine is more commonly used in the treatment of opioid 
dependence, opioid withdrawal symptoms and pain than its intravenous counterpart. 
If concomitant use of buprenorphine and rifampicin is necessary, any risk of 
interaction could be avoided, by choosing an intravenous route of administration of 
buprenorphine. However, it is not possible to successfully administer buprenorphine 
intravenously to patients receiving maintenance therapy with high sublingual 
buprenorphine doses. Furthermore, these patients are prone to staphylococcal 
infections because they often use other opioids and benzodiazepines intravenously. 
If rifampicin treatment is needed during a high dose sublingual buprenorphine 
therapy, the dose of buprenorphine should be significantly higher than normally.  
Another option could be transition to subcutaneous injection depot formula of 
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buprenorphine. These new dosage forms of buprenorphine bypass the extensive first-
pass metabolism of buprenorphine completely and they are probably less prone to 
CYP-mediated interactions.  
6.2 Clinical study 
6.2.1 Methodological considerations 
The aim of this study was to evaluate the efficacy of a transmucosal fentanyl tablet 
compared to placebo in patients undergoing colonoscopy. A total of 150 patients was 
planned to be enrolled in this study. The sample size was determined based on results 
of previous studies (Pambianco et al. 2016; Amer-Cuenca et al. 2011) with a similar 
design and was expected to provide sufficient data to reveal the applicability of 
sublingual fentanyl for relief of discomfort during colonoscopy. The patients were 
randomized into two groups by using the sealed envelope technique. All patients, 
investigators, and staff members involved in the conduct of the study were blinded 
to treatment assignment. The manufacturer of Abstral ® 100 µg provided identical 
placebo tablets, so the blinding was adequate. Patients received the sublingual tablet 
of Abstral ® 100 µg or the identical placebo ten minutes before the procedure. It has 
been shown that first detectable drug concentration in blood after administration of 
a 100 µg sublingual dose of fentanyl is reached in 10.7 minutes (Lennernäs et al. 
2005). However, the maximum drug concentration in blood is reached in 39.7 
minutes and most of the colonoscopies in this study were rather short. The median 
length of the procedure was 15 minutes in the placebo group and 20 minutes in the 
fentanyl group. Patients could have had better pain relief during the procedure, if 
there would have been more time between the administration of the drug and the 
beginning of the colonoscopy. Patients were instructed not to swallow the tablet but 
allow it dissolve completely. Patients were not allowed to drink or eat anything until 
the sublingual tablet was dissolved, but we cannot rule out the possibility that part 
of the drug was nonetheless swallowed.  
Sublingual administration of fentanyl was chosen to avoid the need for 
intravenous access. The bioavailability of sublingual fentanyl is approximately 70%. 
For safety and ethical reasons, we wanted to keep the dose of fentanyl relatively low, 
especially when most patients were opioid naïve. Sublingual fentanyl with the dose 
of 100 µg has been shown to be effective and safe in average-sized adults and also 
in elderly patients with comorbidities (Rauck et al. 2016; 2017). However, the 
bioavailability of sublingual fentanyl varies considerably, and we cannot rule out the 
possibility that the dose was too low, at least in some of the patients. 
All colonoscopies were performed by one of the three experienced endoscopists. 
We tried to avoid a confounding factor i.e. that the skill level of endoscopist would 
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affect our results, by limiting the number of endoscopists to three. It has been shown 
that significant discomfort during colonoscopy is associated with longer 
colonoscope insertion times and longer colonoscope withdrawal times  (Ball et al. 
2015). In this study, there were no major variations in the duration of the 
colonoscopies.  
6.2.2 Measuring pain and sedation 
In this study, the primary outcome variable was the pain experienced by the patient. 
Pain is difficult to measure, because the experience is subjective, but NRS has been 
found to be valid for measuring pain (Jensen, Miller, and Fisher 1998; Ferreira-
Valente, Pais-Ribeiro, and Jensen 2011). The same numerical rating scale was used 
to assess patients’ sedation, unpleasantness, co-operation, progression of the 
procedure and adverse effects even though it has not been validated to measure these 
variables. There are some studies though, that seem to indicate that NRS is slightly 
more sensitive than VAS (Ferreira-Valente, Pais-Ribeiro, and Jensen 2011) and in 
this study, we chose NRS because it is more practical and easier to understand for 
most people than VAS. NRS is also easier to use, when no clear vision, paper or pen 
are needed. 
When pain is assessed using a numerical rating scale, no pain at all is expressed 
as 0 and worst pain imaginable is designated to be 10. Patients were instructed to use 
the scale correctly before any assessments were made. In this study, the median pain 
experienced by the patients was 4.5 [2-7] in the intervention and 5 [3-6.5] in the 
placebo group. In a previous study by Lazaraki et al. patients received either a small 
dose of intravenous fentanyl or midazolam and the mean pain score was 2.59 in the 
fentanyl group and 4.43 in the midazolam group when pain was assessed on a scale 
of 0-10 (Lazaraki et al. 2007). When 1000 mg of intravenous paracetamol and 0.5-1 
µg/kg of intravenous fentanyl were compared in patients undergoing colonoscopy, 
patients assessed the mean pain to be 4.00 after paracetamol and 3.77 in fentanyl 
(Ahmadi et al. 2015). Thus, in our study, the median pain scores were similar to 
those reported elsewhere. The median pain was considered to be moderate, as on 
NRS pain a rating between 4 and 6 is thought to represent moderate whereas pain 7-
10 is classified as severe. 
The maximum pain patients experienced in placebo group was 8 [5-9]; in the 
intervention group it was 7 [4.75-8].  Here, the maximum pain was measured during 
the colonoscopy because afterwards many patients might remember the degree of 
the pain in a different way.  
The median self-assessed sedation level using the NRS-scale was 0 in both 
groups. The sedation level assessed by the endoscopist was 0 [0-1] in both groups 
and the corresponding value assessed by the assisting nurse was 0 [0-1] in the 
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placebo group and 1 [0-2] in the fentanyl group. The comparison of sedation levels 
to other studies is difficult, because most of the studies have combined the opioid 
with midazolam to achieve sedation (Holloway and Logan 1990; Usta et al. 2011). 
There are very few studies where an opioid has been used alone to relieve pain during 
colonoscopy. 
In this study there were no differences in the placebo and intervention groups in 
the levels of measured pain. Patients were not sedated in either group. As there were 
no differences in the placebo and intervention groups, the patients did not experience 
any relief in their procedural pain from the pre-medication with sublingual fentanyl. 
However, only three procedures needed to be interrupted in both groups. Excessive 
pain interrupted the procedure in one patient in the intervention group and two 
patients in the placebo group. We did not administer any rescue medicine and the 
procedure was simply interrupted if the patient experienced unbearable pain.  
Our results suggest that pain is seldom the limiting factor for success in 
colonoscopy, while discomfort and anxiety might be of more importance. It has been 
shown that there is no correlation between lower pain scores and patient satisfaction 
during colonoscopy (Amri et al. 2018). Higher patient satisfaction scores are 
achieved with deeper sedation with propofol (Wang et al. 2013; Zhang, Zhu, and 
Zheng 2018; McQuaid and Laine 2008). 
6.2.3 Limitations of the study 
Recruitment period was very long in this study. Patients were recruited to participate 
in this study between April 2012 and December 2018.  The main reason for this was 
patients’ unwillingness to undergo colonoscopy without sedation and the prohibition 
to drive car after administration of the study drug. Another factor affecting 
recruitment was that the endoscopy unit changed location several times during our 
study and there were limited possibilities for patient recruitment during certain times.  
Patients received the drug ten minutes before the procedure. It has been shown 
that the peak drug concentration in blood after 100 µg of sublingual fentanyl is 
reached in 39.7 minutes with the first detectable concentration in 10.7 minutes, on 
the average (Lennernäs et al. 2005). Here, the median length of the colonoscopy was 
rather short, 15-20 minutes. Patients could have had better pain relief during the 
procedure, if there had been a longer time between the administration of the drug 
and the beginning of the colonoscopy. In this study, the dose of sublingual fentanyl 
was 100 µg, which was considered to be adequate based on previous reports. The 
bioavailability of sublingual fentanyl is approximately 70% but it is known that the 
bioavailability varies considerably between individuals and we cannot rule out the 
possibility that at least in some of the patients, the dose was too low. However, 
regarding the intravenous route, a single dose of 36 µg of intravenous fentanyl has 
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been found to be sufficient prior to colonoscopy (Lazaraki et al. 2007) and compared 
to this study, the effective dose of fentanyl after 100 µg sublingual administration 
should have been enough. On the other hand, the fentanyl dose was the same for all 
the patients. It could have been more beneficial to adjust the fentanyl dose according 
to the patients’ weight. For this purpose fentanyl tablets should have been split and 
administering the exact dose would have been impossible.  
The sublingual route is an effective way to administer some drugs. The drug’s 
effect appears rapidly and extensive first-pass metabolism by CYP enzymes is partly 
avoided which is particularly useful for those drugs which undergo extensive first-
pass metabolism. Unfortunately, the patients in this study were not familiar with the 
sublingual administration of the drug and even though they were instructed to let the 
tablet dissolve completely, it is possible that even a considerable part of the fentanyl 
dose was swallowed.  
6.2.4 Future challenges – sedation or analgesia 
Patients in the present study did not benefit from 100 µg of sublingual fentanyl 
before colonoscopy. Patients in both placebo and intervention groups reported a 
moderate degree of pain. Regardless, almost all procedures were performed 
successfully. The number of interrupted colonoscopies was similar in both groups. 
The intervention had no significant effect on the satisfaction of the endoscopist. 
Sublingual fentanyl did not cause any significant adverse effects or sedation, and the 
hospital stay was not prolonged.  
The results of this study suggest that pain is seldom the limiting factor for success 
in colonoscopy, while discomfort and anxiety might be of more importance. Patients 
placed the highest value on experiencing no pain during the procedure in a study, 
which asked about pre-procedure patient values regarding sedation for colonoscopy. 
(Subramanian, Liangpunsakul, and Rex 2005). However, significantly higher patient 
satisfaction scores were reached when propofol was used for sedation during 
colonoscopy (Zhang, Zhu, and Zheng 2018; Wang et al. 2013; McQuaid and Laine 
2008).  Nonetheless, lower pain scores do not automatically mean better patient 
satisfaction (Amri et al. 2018). The second and third most valued property among 
patients in the study of Subramanian et al. was waking up promptly after the 
procedure combined with going to sleep and not waking until the procedure was 
over. Propofol provides a rapid onset of sedation and patients recover quickly after 
propofol sedation (McQuaid and Laine 2008; Zhang, Zhu, and Zheng 2018). In this 
present study, the patients did not feel sedated in either of the groups and both the 
endoscopist and the assisting nurse also assessed the level of patient sedation to be 
0 in both groups. Moderate or consciousness-maintaining sedation has been found 
to be safer than deep sedation and it also resulted in better cost-efficiency (Lim et al. 
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2019). There are very few studies in which only analgesic drugs have been used to 
treat pain during colonoscopy and there are even fewer placebo-controlled studies. 
In most of the studies, comparing different opioids during colonoscopy, the opioids 
have been used in combination with either midazolam or propofol (Doǧanay et al. 
2017; Deng et al. 2017; Usta et al. 2011). Even in a study where intravenous fentanyl 
alone was used, it was compared to midazolam and not to placebo (Lazaraki et al. 
2007). The comparison of sedation levels to other studies is therefore difficult. We 
are not aware of any studies, where pre-medication before colonoscopy was given 
by any route other than intravenously.  
In global terms, most of the patients undergoing colonoscopy prefer sedation but 
there are countries where sedation is rarely used during colonoscopy (Froehlich et 
al. 2006). However, there is a small group of patients who are motivated to go 
through the procedure without sedation and interestingly, it has been found that 
patients who choose not to have sedation are those least likely to experience 
significant discomfort during the procedure (Ball et al. 2015).  
This present study indicates that sublingual fentanyl, at least as a low-dose 
monotherapy, seems to be ineffective for producing a suitable level of sedation 
and/or analgesia for patients undergoing colonoscopy. The literature at the moment 
suggests that the greatest patient satisfaction scores are achieved when sedation is 
implemented with propofol or dexmedetomidine (Dere et al. 2010; Wang et al. 2013; 
McQuaid and Laine 2008). It might be beneficial also to offer all patients in all 
countries the possibility to undergo colonoscopy without sedation. However, more 
studies where only analgesic drugs are used are needed before any final conclusion 
on this issue can be drawn.  
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7 Conclusions 
1. Compared to placebo, voriconazole increased the mean area under the 
plasma concentration-time curve (AUC0–∞) of sublingual buprenorphine 
by 1.80-fold, its peak concentration (Cmax) by 1.37-fold and its half-life 
(t½) by 1.37-fold. Posaconazole increased the AUC00-∞ of sublingual 
buprenorphine 1.25-fold. Most of the plasma norbuprenorphine 
concentrations were below the limit of quantification (0.05 ng/ml). 
Voriconazole, unlike posaconazole, increased the urinary excretion of 
norbuprenorphine by 1.58-fold but there were no quantifiable amounts of 
the parent buprenorphine in urine. The plasma buprenorphine 
concentrations correlated with the pharmacological effects, but these 
effects did not differ significantly between the voriconazole, 
posaconazole and placebo phases.  
2. Voriconazole increased the mean area under the plasma concentration-
time curve (AUC0-18) of oral buprenorphine by 4.3-fold, its peak 
concentration (Cmax) by 3.9-fold and elevated its excretion into urine. 
Voriconazole also markedly enhanced the Cmax, AUC0-18 and the 
Ae of unconjugated norbuprenorphine, but decreased its renal clearance. 
The effects of voriconazole on parent buprenorphine can be mainly 
explained by inhibition of CYP3A4, but there are indications of additional 
mechanisms. Mild dizziness and nausea occurred during both placebo and 
voriconazole phases 
3. Rifampicin decreased the mean area under the dose-corrected plasma 
concentration time curve (AUC0–18) of sublingual buprenorphine by 25%. 
The presence of rifampicin reduced the bioavailability of sublingual 
buprenorphine from 22% to 16%. The plasma concentrations of 
intravenously administered buprenorphine were not influenced by 
rifampicin. After sublingual and intravenous administration of 
buprenorphine, the amount of norbuprenorphine excreted into urine 
decreased by 65% and 52% in the presence of rifampicin, respectively. 
Adverse effects were frequent. 
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4. The effects of voriconazole, posaconazole and rifampicin on parent 
buprenorphine can be mainly explained by inhibition and induction of 
CYP3A4, but there are indications of additional mechanisms. The 
activities of UGTs an P-gp can be enhanced by rifampicin, voriconazole 
and posaconazole and this can influence the metabolism of 
buprenorphine. 
5. Concomitant use of voriconazole or rifampicin and sublingual 
buprenorphine may result in clinically relevant interactions.  
Buprenorphine doses should be adjusted properly if concomitant use is 
necessary.  
6. Patients do not benefit from a dose of 100 µg of sublingual fentanyl before 
undergoing colonoscopy. There were no differences between placebo and 
the intervention groups in any of measured variables. The median pain 
experienced by patients, measured with an NRS-scale was 4.5 in the 
intervention group and 5 in the placebo group. Neither sedation, 
desaturation nor signs of a decreased respiratory rate were observed in 
either of the groups. The majority of the colonoscopies could be 
completed even though patients did not benefit from medication. 
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Kiitokset 
Tämän väitöskirjan kolme ensimmäistä työtä toteutettiin anestesiologian, 
tehohoidon, ensihoidon ja kivunhoidon sekä farmakologian ja lääkehoidon 
laitoksilla Turun yliopistossa ja Turun Yliopistollisessa keskussairaalassa vuosina 
2011-2014. Neljännen työn kliininen osuus toteutettiin Turun Yliopistollisen 
keskussairaalan tähystysyksikössä vuosina 2012–2018.  
Haluan kiittää kaikkia kolmea ohjaajaani kärsivällisyydestä ja tuesta 
väitöskirjaprosessin aikana.  
Apulaisprofessori Teijo Saari on jaksanut kannustaa minua koko prosessin ajan 
ja hänen apunsa on ollut korvaamatonta. Erityisesti arvostan hänen osaamistaan ja 
ymmärtämystään statistiikan osa-alueella.  
Professori Klaus Olkkola on ollut erinomainen ja innostava ohjaaja. Helsinkiin 
siirtymisestään huolimatta hän on ollut koko ajan läsnä väitöskirjaprosessin edetessä 
ja antanut apuaan ja asiantuntemustaan projektiin aina kun sitä on tarvittu.  
Dosentti Kari Laine on rautainen farmakologian ammattilainen ja arvostan 
erityisesti hänen suoria, selkeitä ja rehellisiä kommenttejaan sekä osatöiden että itse 
väitöskirjan käsikirjoituksista niiden muotoutuessa lopulliseen muotoonsa.  
Haluan kiittää myös seurantaryhmän jäseniä. Dosentti Nora Hagelberg antoi 
minulle korvaamatonta tukea ja ohjausta aivan urani alkuvaiheessa sekä kliinisessä 
työssä, että tutkimustyön aloittamisessa. Edesmennyt Professori Riku Aantaa teki 
minuun suureen vaikutuksen tehokkuudellaan ja suoruudellaan. Opin häneltä todella 
paljon sekä tutkimustyön että lasten anestesiologian saralta.  
Haluan kiittää lämpimästi Tuija Hemmilää avusta tutkimusten suunnittelussa, 
vapaaehtoistutkimusten toteuttamisesta ja tuesta koko väitöskirjaprojektin ajan. 
Tuijan apu teki kolmen ensimmäisen osatyön toteuttamisen minulle ja perheelleni 
huomattavasti miellyttävämmäksi. Kiitokset myös Tuukka Saarikoskelle, jonka apu 
oli korvaamatonta kun aloitin ensimmäisen vapaaehtoistyön toteuttamista.  
Suuret kiitokset myös muille osatöiden kirjoittajille. Kristiina Kuusniemi, Janne 
Backman, Jouko Laitila ja Pertti Neuvonen antoivat kaikki asiantuntemuksensa 
ryhmän käyttöön tutkimuksia toteutettaessa.  
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Väitöskirjan esitarkastajina toimivat Dosentti Maija Kaukonen ja Dosentti Jari 
Lilja. Kiitokset heille erinomaisen selkeistä korjausehdotuksista, ne tekivät 
väitöskirjasta paljon paremman.  
Haluan kiittää myös tutkimukseemme osallistuneita gastrokirurgeja. Pirita 
Varpe ja Heikki Huhtinen toteuttivat suurimman osan neljännen osatyön 
kolonoskopioista ja itse asiassa koko idea neljänteen osatyöhön tuli heiltä.  
Tutkimuksen loppuaikoina saimme apua potilaiden rekrytointiin syventävien töiden 
tekijältä. Kiitokset Emmi Karrulle, jonka työpanos nopeutti huomattavasti 
tutkimuksen loppuun saattamista. Lämmin kiitos laboratoriohoitaja Elina Kahralle. 
Hänen ammattitaitoinen työpanoksensa oli korvaamaton kolmen ensimmäisen 
osatyön aineiston keräämisessä. Lisäksi nautin todella hänen seurastaan 
tutkimuspäivien aikana. Haluan kiittää myös ystävääni Eliisa Löyttyniemeä, ilman 
hänen apuaan tuloskuvien tuottamisessa omistaisin luultavasti jo useita harmaita 
hiuksia.  
Jokainen tutkimuksiini osallistunut vapaaehtoinen koehenkilö ja potilas 
ansaitsee myös suuret kiitokset.  
Kliinisessä työssä minulla on ilo työskennellä uskomattoman kannustavassa ja 
tiiviissä työyhteisössä. Sanna Vilo on aina yhtä positiivinen ja ymmärtäväinen 
esimies, kollega ja ystävä. Kiitokset hänelle ymmärryksestä ja kannustuksesta 
väitöskirjaprosessin edetessä, kiitokset vaellusseurasta, koiralenkeistä ja monesta 
muustakin asiasta. Uskomattomat kädentaidot omaava Markku Taittonen tuo oman 
lisämausteensa tiiviiseen lastenanestesiologitiimiin, kiitokset hänelle aina iloisesta 
mielestä ja ammatillisesta opista vuosien varrella. Olli Vänttinen jaksaa pitää yllä 
porukan innostunutta mielialaa ja hänen verbaalinen lahjakkuutensa pitää muidenkin 
mielen vireänä. Kiitokset hänelle välittämisestä, joka ilmenee meidän kaikkien 
tuntemalla tavalla. Anssi Heino on vakaa ja luotettava kollega, joka uskaltaa tarpeen 
tullen kertoa rehellisen mielipiteensä. Kiitokset hänelle aina yhtä hyvin sujuvasta 
yhteistyöstä ja monesta hyvästä keskustelusta liittyen niin tutkimus- kuin muihinkin 
arkipäiväisiin asioihin. Monna Myllykangas on porukkamme juniori, jolla on asenne 
kohdillaan. Kiitokset mutkattomasta kanssakäymisestä ja raikkaan tuulahduksen 
tuomisesta lastenanestesiologiporukkaan. Ja suuri kiitos kuuluu tietysti myös 
lastenanestesiologiryhmän muumimammalle, Tuula Mannerille. Hän jaksaa nähdä 
kaikissa ja kaikessa asioiden hyvät ja valoisat puolet ja jaksaa aina kannustaa 
oikeastaan ihan missä tahansa asiassa. Eikä pidä unohtaa aina yhtä empaattista lasten 
leikkausosaston henkilökuntaa, on ilo työskennellä kanssanne.   
Sydämelliset kiitokset hyville ystävilleni ammatillisen uran ja tutkimuksen teon 
eri vaiheiden aikana. Minna Kallioisen kanssa olemme kulkeneet melko samaa 
vauhtia läpi erikoistumisen ja matkan varrelle on mahtunut kaikenlaista. Minnan 
kanssa olen voinut ventiloida niin työ- kuin yksityisasioita ja aina näiden 
juttutuokioiden jälkeen olo on kevyempi. Katrin Sisa on yksi niistä harvoista 
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ihmisistä, joiden kanssa olen löytänyt yhteisen sävelen oikeastaan heti 
ensitapaamisella. Kiitokset Katrinille monista hauskoista hetkistä, arvostan 
erityisesti hänen suorapuheisuuttaan ja rohkeuttaan. Kiitokset Riku Anttilalle ja Atte 
Koskiselle, jotka pelkällä läsnäolollaan tekevät päivistä hauskempia ja joiden 
seurasta pidän huomattavasti keskimääräistä enemmän. Haluan myös kiittää 
Arimatias Raitiota vertaistuesta väitöskirjaprojektiemme loppusuoran edetessä rinta 
rinnan. Lämmin kiitos lapsuuden ystävälleni Marille, jonka kanssa tehdyistä pitkistä 
kävelylenkeistä ja niiden aikana käydyistä keskusteluista olen nauttinut paljon.  
Kiitokset Panu Uusalolle ja Ulla Ahlmen-Laiholle avusta käytännön asioiden 
kanssa väitöskirjaprojektin edetessä. Kiitokset myös kollega Matias Rantaselle, 
jonka kanssa käydystä keskustelusta sain viimeisen tarvittavan sysäyksen 
väitöskirjaprojektin maaliin viemiselle. Kiitoksensa ansaitsee myös koko Totekin 
anestesialääkärikunta, on kunnia kuulua tähän kirjavaan joukkoon.  
Urani alkuvaiheita ohjailivat Salon aluesairaalassa Matti Helkiö, Jyrki Tikkanen 
ja Ari Alho. Haluan kiittää heitä myönteisen ilmapiirin luomisesta nuoren 
anestesialääkärin kasvulle. Kiitokset myös myötämielisyydestä tutkimusprojektin 
aloittelulle jo Salon erikoistumisvuosina. Lämmin kiitos Tomi Vainiolle, jolta sain 
hyvät eväät kliinisen anestesiatyön aloittamiseen erikoistumiseni ensimmäisen 
puolen vuoden aikana.  
Suurimmat kiitokset kuuluvat perheelleni. Vanhempani Pirjo ja Pertti Lepistö 
eivät ole ikinä yrittäneet ohjata minua mihinkään tiettyyn suuntaan elämässäni, vaan 
ovat tukeneet minua kaikissa pyrkimyksissäni ja antaneet minun tehdä täysin omat 
valintani. Veljeni Juha-Matti on aina ollut tärkeä osa elämääni ja tätä nykyä siihen 
kuuluvat myös hänen vaimonsa Anniina ja tytär Aada sekä tätä kirjoittaessa pian 
syntyvä pikkuveli Aadalle. Erityisesti Aada on viime vuosina riemastuttanut meitä 
verbaalisella lahjakkuudellaan ja serkkurakkaudellaan.  
Mieheni Robert ja poikani Joonatan ja Elias ansaitsevat erityiskiitokset. He ovat 
vuosien mittaan jaksaneet olla ymmärtäväisiä ja kannustavia kaikkia projektejani 
kohtaan, oli kyse sitten erikoistumisesta, väitöskirjan teosta tai vapaaehtoistyöstä 
maailmalla. Kaikista muista projekteista huolimatta perhe on aina se tärkein ja olen 
erittäin ylpeä molempien poikieni menestyksestä oman elämänsä tärkeillä saroilla.  
Tämä väitöskirjatyö on saanut rahallista tukea apurahojen muodossa Suomen 
Anestesiologiyhdistykseltä, Suomen Kivuntutkimusyhdistykseltä, Suomen 
lääketieteen säätiöltä, Paulon säätiöltä, Turun yliopistosäätiöltä ja Turun Yliopiston 
yhdistetyltä tutkimusrahastolta. Haluan kiittää kaikkia apurahan myöntäjiä, apurahat 
mahdollistivat tutkimusvapaan pitämisen, joka puolestaan mahdollisti väitöskirjan 
valmistumisen 
Turku, kesäkuu 2020 
Mari Fihlman 
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